 
 
 
CLINICAL STUDY PROTOCOL  
A Multicenter, Randomized, Double Blind, Placebo Controlled Stu dy to 
Assess the Efficacy  and Safety of  Acthar® Gel in Subjects With 
Persistently Active Systemic  Lupus Erythematosus  Despite Moderate Dose 
Corticosteroid s 
 
Protocol Number : MNK 14304067  
Date of Original Protocol : 02 June  2016  
Date of Protocol Revision:  04 August  2016  
Date of Protocol Revision:   26 August 2016  
Date of Protocol Revision:  01 June 2017  
 
 
 
 
Mallinckrodt ARD , Inc. 
675 McDonnell Boulevard  
Hazelwood, MO 63042  
United States of America  
 
  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 2 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 Table of Contents  
1 DISCLOSURE STATEMENT  ................................ ................................ ............................  7 
1.1 Restricted Distribution of Documents  ................................ ................................ ............  7 
2 CONTACTS  ................................ ................................ ................................ .......................  8 
2.1 Emergency Cont acts ................................ ................................ ................................ ....... 8 
2.2 Additional Contacts  ................................ ................................ ................................ ........  9 
3 SPONSOR SIGNATURE  ................................ ................................ ................................ . 10 
4 INVESTIGATOR SIGNATURE  ................................ ................................ ....................... 11 
5 SUMMARY OF CHANGES  ................................ ................................ ............................  12 
6 ABBREVIATIONS  ................................ ................................ ................................ ..........  13 
7 SYNOPSIS  ................................ ................................ ................................ .......................  15 
8 STUDY SCHEMATIC AND SCHEDULE OF EVENTS  ................................ ................  19 
8.1 Study Schematic  ................................ ................................ ................................ ...........  19 
8.2 Schedule of Study Events  ................................ ................................ .............................  20 
9 ETHICAL CONSIDERATIONS  ................................ ................................ ......................  22 
9.1 Institutional Review Board/Independent Ethics Committee  ................................ ........  22 
9.2 Ethical Conduct of the Study  ................................ ................................ ........................  22 
9.3 Subject Information and Consent  ................................ ................................ .................  22 
10 BACKGROUND INFORMATION AND RATIONALE  ................................ .................  23 
10.1  Systemic Lupus Erythematosus  ................................ ................................ ....................  23 
10.2  Product Description  ................................ ................................ ................................ ...... 27 
10.3  Dosage and Administration  ................................ ................................ ..........................  27 
10.4  Rationale  ................................ ................................ ................................ .......................  27 
10.5  Risks and Benefits  ................................ ................................ ................................ ........  28 
11 OBJECTIVES  ................................ ................................ ................................ ...................  29 
11.1  Primary Objective  ................................ ................................ ................................ .........  29 
11.2  Secondary Objectives  ................................ ................................ ................................ ... 29 
11.3  Exploratory Objectives  ................................ ................................ ................................ . 29 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 3 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 11.4  Approximate Duration of Subject Participation  ................................ ...........................  29 
12 STUDY DESIGN  ................................ ................................ ................................ .............  29 
12.1  Description  ................................ ................................ ................................ ...................  29 
12.2  Approximate Duration of Study  ................................ ................................ ...................  30 
12.3  Approximate Number of Subjects  ................................ ................................ ................  30 
13 SELECTION OF SUBJECTS  ................................ ................................ ..........................  30 
13.1  Inclusion Criteria  ................................ ................................ ................................ ..........  30 
13.2  Exclusion Criteria  ................................ ................................ ................................ .........  32 
13.3  Screen Failure  ................................ ................................ ................................ ...............  34 
14 PRIOR AND CONCOMITANT MEDICATIONS/TREATMENTS  ................................  35 
14.1  Permitted Concomitant Medications  ................................ ................................ ............  35 
14.2  Prohibited Concomitant Medications  ................................ ................................ ...........  35 
15 PROCEDURES  ................................ ................................ ................................ ................  36 
15.1  Screening Visit (Study Days -28 to -1) Procedures  ................................ ......................  36 
15.2  Randomization Visit (Week 0) and First Dose Procedures  ................................ ..........  37 
15.3  Week 2 (± 3 days) and 6 (± 3 days) Procedures  ................................ ...........................  38 
15.4  Week 4 (± 3 days) and 20 (± 5 days) Procedures  ................................ .........................  38 
15.5  Week 8 (± 3 days) and 16 (± 5 days) Procedures  ................................ .........................  39 
15.6  Week 12 (± 5 days) Procedures  ................................ ................................ ....................  39 
15.7  Week 24 (± 5 days)/Early Termination Procedures  ................................ ......................  40 
15.8  Follow -up Visit - Week 28 (± 5 days)  ................................ ................................ ..........  41 
16 INVESTIGATIONAL MEDICINAL PRODUCT (Study Drug) ................................ ...... 41 
16.1  Methods of Assigning Subjects to Treatment Groups  ................................ ..................  41 
16.1.1  Randomization and Stratification  ................................ ................................ .............  41 
16.1.2  IXRS  ................................ ................................ ................................ .........................  42 
16.2  Emergency Identification of Investigational Medicinal Product  ................................ .. 42 
16.3  Dosing Procedures  ................................ ................................ ................................ ........  43 
16.3.1  Treatment Discontinuation  ................................ ................................ .......................  43 
16.4  Storage of Clinical Supplies  ................................ ................................ .........................  44 
16.5  Drug Accountability  ................................ ................................ ................................ ..... 44 

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 4 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 16.6  Compliance Monitoring ................................ ................................ ................................  44 
17 EFFICACY ASSESSMENTS AND PROCEDURES  ................................ ......................  44 
17.1  Physician Completed Assessments  ................................ ................................ ...............  44 
17.1.1  Systemic Lupus Erythematosus Disease Activity Index -2000  ................................ . 45 
17.1.2  British Isles Lupus Assessment Group 2004  ................................ ............................  45 
17.1.3  Physicians Global Assessment  ................................ ................................ .................  45 
17.1.4  SELENA Flare Index  ................................ ................................ ................................  46 
17.1.5  Cutaneous Lupus Erythematosus Disease Area and Severity Score - Activity  .........  46 
17.1.6  28 Joint Count  ................................ ................................ ................................ ...........  46 
17.2  SLE Responder Index  ................................ ................................ ................................ ... 46 
 ................................ ................................ ....  
 ................................ ...............................   
 ................................ ................................ ...................
19 SAFETY ASSESSMENTS AND PROCEDURES  ................................ ..........................  48 
19.1  Adverse Events  ................................ ................................ ................................ .............  48 
19.2  Medical and Surgical History  ................................ ................................ .......................  48 
19.3  Current Medical Conditions  ................................ ................................ .........................  49 
19.4  Physical Examination  ................................ ................................ ................................ ... 49 
19.5  Height and Weight  ................................ ................................ ................................ ........  49 
19.6  Vital Signs  ................................ ................................ ................................ ....................  49 
19.7  Clinical Laboratory Tests (Chemistry, Hematology and Urinalysis), HbA1c, IGRA, 
 Pregnancy Tests, ; and C3, C4, 
and anti -ds DNA antibodies ................................ ................................ ..........................  50 
19.8  Hospital Admissions  ................................ ................................ ................................ ..... 52 
................................ ................................ .............   
  ................................ ................................ ................................ .................   
 ................................ ................................ ................................ ... 52 
21 STATISTICAL METHODS AND PLANNED ANALYSIS  ................................ ............  52 
21.1  General Considerations  ................................ ................................ ................................  52 
21.2  Analysis Populations  ................................ ................................ ................................ .... 53 
21.3  Efficacy Endpoints  ................................ ................................ ................................ ....... 53 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 5 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 21.3.1  Primary Efficacy Endpoint  ................................ ................................ .......................  53 
21.3.2  Secondary Efficacy Endpoints  ................................ ................................ ..................  53 
21.3.3  Exploratory Endpoints  ................................ ................................ ..............................  54 
21.4  Safety Endpoints  ................................ ................................ ................................ ...........  54 
21.5  Subject Characteristics  ................................ ................................ ................................ . 54 
21.5.1  Demographics  ................................ ................................ ................................ ...........  54 
21.5.2  Medical and Surgical History  ................................ ................................ ...................  54 
21.5.3  Prior and Concomitant Medications  ................................ ................................ .........  55 
21.5.4  Subject Disposition and Exposure to Study Drug  ................................ ....................  55 
21.6  Efficacy Analysis  ................................ ................................ ................................ ..........  55 
21.7  ................................ ..........................  55 
21.8  Safety Analysis  ................................ ................................ ................................ .............  56 
21.8.1  Adverse Events  ................................ ................................ ................................ .........  56 
21.8.2  Clinical Laboratory Tests;  
 ................................ ................................ ................................ .................  56 
21.8.3  Vital Signs  ................................ ................................ ................................ ................  56 
21.8.4  Hospital Admissions  ................................ ................................ ................................ . 56 
21.8.5  Other Safety Analysis  ................................ ................................ ...............................  57 
21.9  ................................ ................................ ...............................  57 
21.10  Interim Analysis ................................ ................................ ................................ ............  57 
21.11  Statistical Power and Sample Size Considerations  ................................ ......................  57 
21.12  Deviations From Statistical Analysis Plan  ................................ ................................ ... 57 
22 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  ................................ .........  57 
22.1  Safety  ................................ ................................ ................................ ............................  57 
22.2  Definitions  ................................ ................................ ................................ ....................  58 
22.3  Adverse Event and Serious Adverse Event Classifications  ................................ ..........  60 
22.4  Adverse Event and Serious Adverse Event Recording and Reporting  .........................  61 
22.5  Adverse Events of Spe cial Interest  ................................ ................................ ...............  63 
22.6  Pregnancy Reporting  ................................ ................................ ................................ .... 64 
23 SUBJECT DISCONTINUATION OR WITHDRAWAL  ................................ .................  64 
23.1  Subject Withdrawal  ................................ ................................ ................................ ...... 64 
24 STUDY SUSPENSION, TERMINATION, AND COMPLETION  ................................ . 66 

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 6 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 25 PROTOCOL AMENDMENTS  ................................ ................................ ........................  66 
26 QUALITY CONTROL AND ASSURANCE  ................................ ................................ ... 66 
26.1  Study and Study Site Discontinuation Criteria  ................................ .............................  66 
27 DIRECT ACCESS, DATA HANDLING, AND RECORD -KEEPING  ............................  67 
27.1  Investigator  ................................ ................................ ................................ ...................  67 
27.2  Sponsor  ................................ ................................ ................................ .........................  67 
28 SUBJECT INJUR Y ................................ ................................ ................................ ..........  68 
29 RECORDS RETENTION  ................................ ................................ ................................  68 
30 BIOLOGICAL SAMPLES  ................................ ................................ ...............................  68 
31 PUBLICATION POLICY  ................................ ................................ ................................ . 68 
31.1  Sponsor ’s Publication Policy  ................................ ................................ ........................  68 
31.2  Investiga tor’s Ability to Publish  ................................ ................................ ...................  69 
32 REFERENCES  ................................ ................................ ................................ .................  70 
33 Attachments  ................................ ................................ ................................ ......................  74 
33.1  Attachmen t 1: Clinical Laboratory Tests  ................................ ................................ ...... 74 
 
List of Tables  
Table 8 -1: Schedule of Study Events  ................................ ................................ ...............  20 
Table 22 -1:  Adverse Event Relationships  ................................ ................................ ..........  60 
Table 22 -2:  Adverse Event Severity Grades  ................................ ................................ ...... 60 
Table 22 -3: Reporting Requirements for A dverse Events  ................................ ..................  62 
 
List of Figures  
Figure 8 -1: Study Overview  ................................ ................................ ..............................  19 
 

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 7 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 1 DISCLOSURE STATEMENT  
1.1 Restricted Distribution of Documents  
This document contains information that is confidential and proprietary to the sponsor. This 
information is being provided to the investigator solely for the purpose of evaluating and/or 
conducting a clinical study for the sponsor. The investigator  may dis close the contents of this 
document only to study personnel under his/her supervision, institutional review boards 
(IRBs) /independent ethics committees (IECs) , or duly authorized representatives of 
regulatory agencies for this purpose under the condition t hat they maintain confidentiality. 
The contents of this document may not be used in any other clinical study, disclosed to any 
other person or entity, or published without the prior written permission of the sponsor. The 
foregoing shall not apply to disclo sure required by any regulations; however, the investigator  
will give prompt notice to the sponsor of any such disclosure. All other nonpublic 
information provided by the sponsor, as well as any information that may be added to this 
document, also is confi dential and proprietary to the sponsor and must be kept in confidence 
in the same manner as the contents of this document.  
  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 8 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 2 CONTACTS  
2.1 Emergency Contacts  
Role in Study  Name  Contact Information  
Primary Contact:  
Medical Monitor   MD  Toll Free Number:   
Toll Number  
Email:     
FAX:   
Secondary Cintact:  
Medical Monitor    MD  Toll Free Number:   
Toll Number  
Email:   
FAX:   
 
Please see next page for additional telephone contact numbers in Section 2.2. 
Please see Section  22.4 for detailed information regarding the Ser ious Adverse Event (SAE) 
Reporting Requirements for this study.  
SAE reporting fax:   
SAE confirmation email:    

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 9 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 2.2 Additional Contacts  
 
  Role in Study  Name  Contact Information  
Clinical Trial 
Manager   Telephone:    
E-mail:  
Clinical  Technical  
Lead   PhD  Telephone:   
E-mail:  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 10 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 3 SPONSOR SIGNATURE  
My signature, in conjunction with the signature of the investigator , confirms the agreement of 
both parties that the clinical stud y will be conducted in acc ordance with the protocol and 
applicable laws and other regulations including, but not limited to, t he International Council 
for Harmonisation (ICH) Guideline for Good Clinical Practice (GCP), the US C ode of 
Federal Regulations (CFR)  (where applicable ), all applicable national and local regulations , 
protections for privacy, and generally accepted ethical  principles for human research such as 
the Declaration of Helsinki . 
Nothing in this document is intended to limit the authority of a physician to provide 
emergency medical care.  
 
 
Sponsor Signature   Date of Signature  
(DD Month YYYY)  
 PhD    
Sponsor Name (print)    
  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 11 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 4 INVESTIGATOR SIGNATURE  
My signature  confirms  that the clinical study will be conducted in accordance with the 
protocol and applicable laws and other regulations including, but not limited to, the 
International Co uncil for  Harmonisation (ICH) Guideline for Good Clinical Practice ( GCP), 
the US Code of Federal Regulations (CFR)  (where appropriate) , all applicable  national and 
local regulations, protections for privacy, and generally accepted ethical principles such as 
the Dec laration of Helsinki . 
Nothing in this document is intended to limit the authority of a physician to provide 
emergency medical care.  
 
 
 
Investigator ’s Signature   Date of Signature  
(DD M onth YYYY)  
 
   
Investigator ’s Name and Title (print)    
 
  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 12 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 5 SUMMARY OF CHANGES  
 
1. Updated the pharmacovigilance email address.  
2. Updated the approximate number of study centers from 45 to 60.  
3. Updated the Schedule of Events to include: a) footnote “e” (positive urine test after 
randomization confirmed by serum pregnancy test) and b) footnote “f”(autoantibody 
testing at screening) . 
4. Added new inclusion criterion #8, and removed original inclusion criteria # 8 and #  9 
in Section 13.1 . 
5. Updated t he reporting of adverse events for  physical examinations done between 
screening and randomization  in Section 1 9.4. 
6. Updated clinica l laboratory tests in Section 19 .7. 
7. Updated subject withdrawal criteria in Section 2 3.1. 
 
  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 13 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 6 ABBREVIATIONS  
Abbreviation  Term  
2x/week  Twice a week  
ACTH  Adrenocorticotropic h ormone  
AE Adverse e vent 
ALT Alanine  aminotransferase  
ANC  Absolute  neutrophil  count 
AST  Aspartate  aminotransferase  
BAFF  B cell activity factor  
BILAG -2004  British Isles Lupus Assessment Group -2004  
CFR  Code of Federal Regulations  
CLASI  Cutaneous Lupus Erythematosus Disease Area and Severity Score  
CNS  Central nervous system  
CTX -I C-terminal crosslinking telopeptide of Type I collagen  
ECG  Electrocardiogram  
eCRF  Electronic case report form 
FDA  Food and Drug Administration  
HbA1c Glycosylated hemoglobin  
HBsAg  Hepatitis B surface antigen  
HBcAb  Hepatitis B core antibody  
HCV  Hepatitis C virus antibody  
HCV PCR  Hepatitis C virus polymerase chain reaction  
HIPAA  Health Insurance Portability and Accountability Act  
hSLEDAI  Hybrid Systemic Lupus Erythematosus Disease Activity Index  
ICF Informed consent f orm 
ICH International Co uncil for  Harmonisation  
ID Identification  
IEC Independent Ethics Committee  
IFN-alpha  Interferon alpha  
Ig Immunoglobulin  
IGRA  Interferon gamma release assay  
IL Interleukin  
IMP Investigational medicinal product  
IRB Institutional Review Board  
IV Intravenous, intravenously  
IXRS  Interactive  Phone/Web  Response  System  
MCR  Melanocortin  receptor  
mITT  Modified intent -to-treat 
MM Medical monitor  
NSAID  Nonsteroidal anti -inflammatory drugs  
PGA  Physician ’s Global Assessment  
PINP  N-terminal propeptide of Type I collagen  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 14 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 Abbreviation  Term  
QOL  Quality of life  
SAE  Serious adverse event 
SC Subcutaneous , subcutaneously  
SELENA  Safety of Estrogens in Lupus Erythematosus  Natio nal Assessment  
SFI SELENA Flare Index  
SLE Systemic Lupus Erythematosus  
SLEDAI -2K Systemic Lupus Erythematosus Disease Activity Index -2000  
SRI Systemic Lupus Erythematosus Responder Index  
sVCAM -1 Soluble vascular cell adhesion molecule -1 
TB Tuberculosis  
TEAE  Treatment -emergent adverse event  
U Unit( s) 
US United States  
ULN  Upper  limit of normal 
WPAI  Work Productivity and Activity Impairment Questionnaire  
 
  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 15 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 7 SYNOPSIS   
Study Title: A Multicenter, Randomized, Double Blind, Placebo Controlled  Study to Assess the Efficacy  
and Safety of  Acthar® Gel in Subjects With Persistently Activ e Systemic  Lupus Erythematosus  Despite 
Moderate Dose Corticosteroids  
Protocol Number: MNK 14304067  Type: Phase 4 (US)/ Phase 2 (Outside the US)  
Condition/Disease:  Systemic Lupus Erythematosus  
Approximate Number of Subject s: 162 
 Approximate Duration of Subject  Participation: 32 weeks 
Approximate Number of Study  Centers:  
60 globally  Approximate Duration of Study:  3 years  
 
Design:  
This is a randomi zed, placebo controlled, double blind study. Following a screening period of up to 28 days, 
subjects with persistently active systemic lupus erythematosus ( SLE) and moderate to severe rash and/or 
arthritis despite  receiving  corticosteroid s (7.5 mg to 30 mg per day of prednisone or equivalent) for ≥ 4 weeks 
prior to screening , will be randomized in a 1:1 ratio to receive 1 mL ( 80 U nits [U]) of Acthar or matching 
placebo. At randomization, subjects will be stratified by prednisone equivalent dose ( ≤ 20 mg/day vs > 20 
mg/day)  and by location (U nited States [U S] or outside the US ). During Weeks 1 to 4, 1 mL ( 80 U ) of Acthar 
or volume matched  placebo will be administered subcutaneously ( SC) every other day. For the remainder of 
the study (Weeks 5  to 24), Acthar 1 mL ( 80 U ) or volume  matched  placebo  will be administered SC 
2x/week. The primary efficacy endpoint is the SLE Responder  Index ( SRI) at Week  16. Corticosteroid taper 
will be encouraged between Weeks 16 and 24. All subjects will have a follow -up visit 28 (± 5) days  after the 
last dose of study drug.  
Objectives:   
Primary  Objective  
 To determine  the ability of Acthar to reduce disease activity  as measured by SRI,  in subjects with 
SLE requiring moderate dose corticosteroids for persistently active disease.  
Secondary Objectives  
 To assess the impact of Acthar on disease activity, measured by the Systemic Lupus Erythematosus 
Disease Activity Index -2000 ( SLEDAI -2K), British Isles Lupus Assessment Group -2004 (BILAG -
2004 ), and Physician’s Global Assessment ( PGA ), in subjects with SLE requiring moderate dose 
corticosteroids for persistently active dise ase. 
 To assess the time to response to Acthar in subjects with SLE requiring moderate dose 
corticosteroids for persistently active disease.  
 To further assess the safety and tolerability of Acthar in subjects with SLE requiring moderate dose 
corticosteroids  for persistently active disease.  
Exploratory Objectives  
  
 
  
  
Entry Criteria :  
Male or nonpregnant, nonlactating female subjects 18 years of age or older with a diagnosis of SLE 
according to the American College of Rheumatolo gy revised criteria (fulfilled ≥ 4 criteria) and active disease 
defined as total SLEDAI -2K score ≥ 6 and clinical SLEDAI -2K (excluding laboratory domains) score of ≥ 4 
at the time of  screening and  randomization (p oints for arthritis and/or  rash must be pre sent at b oth screening 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 16 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 Study Title: A Multicenter, Randomized, Double Blind, Placebo Controlled  Study to Assess the Efficacy  
and Safety of   Acthar® Gel in Subjects With Persistently Activ e Systemic  Lupus Erythematosus  Despite 
Moderate Dose Corticosteroids  
Protocol Number: MNK 14304067  Type: Phase 4 (US)/ Phase 2 (Outside the US)  
Condition/Disease:  Systemic Lupus Erythematosus  
and randomization ), and  a BILAG -2004 score  of A or B in the in the mucocutaneous and/or musculoskeletal 
body systems  at screening  and randomization . Subjects must have a documented history of a positive 
antinuclear antibody  (ANA)  or a screening result of a positive ANA test by immunofluorescent assay (IFA) 
with a titer ≥ 1:80 or an equivalent assay ; or a documented history or positive screening result of elevated 
anti-dsDNA or ENA antibodies (e.g., anti -Smith, SSA, SSB, RNP). . Subjects with Type 1 or Type 2 
diabetes, active central nervous system manifestations of SLE or active lupus nephritis , tuberculosis , history 
of hepatitis, peptic ulcer, active infection, or any contraindication for Acthar will be excluded.  Subjects must  
exhibit disease activity despite being on a stable daily dose of a corticosteroid (7.5 mg to 30 mg per day 
[inclusive] of prednisone or prednisone equivalent) for  at least 4 weeks prior to the Screening V isit.  
Subjects may be taking antimalarials  and nonsteroidal anti -inflammatory drugs  if they are on a stable dose 
for at least 4 weeks prior to the Screening Visit and will remain on that dose throughout the study. Subjects 
may be taking methotrexate, azathioprine, and/or mycophenolate mofetil if they are on a stable dose for  at 
least 8 weeks prior to the Screening V isit and will remain on that dose throughout the study.  Subjects must 
not have received any steroid injection (intramuscular, intraarticular, or intravenous ) within the 4 weeks prior 
to the Screening V isit. Subjects must not have received cyclosporine, oral corticosteroid doses > 30 mg per 
day of prednisone  or equivalent, or any non -biologic investigational drug within the 3 months prior to the 
Screening  Visit . Subjects must not have receive d intravenous immunoglobulin  or plasmapheresis within the 
4 months prior to the Screening Visit . Subjects must not have received cyclophosphamide,  abatacept,  B cell 
targeted therapies  (anti-CD-22 agents [epratuzumab ] or belimumab), B cell depleting therapy (rituximab or 
other anti -CD20 agents, or anti -CD52 agents [alemtuzumab]) , or any biologic investigational age nt within 
the 6 months  prior  screening.  
Concomitant Medications  and Treatments :  
Subjects must remain on stable daily dose of prednisone or prednisone equivalent through Week 16  of the 
study . Taper of corticosteroid is encouraged between Weeks 16 and 24 as clinically indicated.  
All other background medications for SLE must remain stable throughout the study.  
No new immunosuppressant therapies  or other new treatments for SLE may be initiated during the study.  
Subjects are not permitted to receive live or live -attenuated vaccines during the study.  
All medications and nondrug therapies (eg, blood transfusions, oxygen supplementation) taken from 30 days 
prior to the  Screening Visit and  throughout the study will be recorded.   
Study Drug  and Treatment Administration:  
Acthar is a sterile preparation of  purified adrenocorticotropic hormone (ACTH) analogue formulated in a gel 
for repository administration . Acthar and its matching placebo will be supplied by the sponsor and 
administered SC as follows in this study:  
Treatment A: Acthar 1 mL (80 U ) administered  SC every other day  from Week 0  to 4 and  2x/week  from  
Weeks 5 to 24.  
Treatment B: Placebo  1 mL  administered SC every other day  from Week 0 to 4 and  2x/week  from Weeks 5  
to 24.  
Efficacy Evaluation s: 
The following efficacy assessments will be evaluated:  SRI, SLEDAI -2K, BILAG -2004, PGA , Safety of 
Estrogens in Lupus Erythematosus  National Assessment ( SELENA ) Flare Index (SFI) , Cutaneous Lupus 
Erythematosus Disease Area and Severity Score (CLASI),  28 Joint Count, and  prednisone usage after 
Week  16. 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 17 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 Study Title: A Multicenter, Randomized, Double Blind, Placebo Controlled  Study to Assess the Efficacy  
and Safety of  Acthar® Gel in Subjects With Persistently Activ e Systemic  Lupus Erythematosus  Despite 
Moderate Dose Corticosteroids  
Protocol Number: MNK 14304067  Type: Phase 4 (US)/ Phase 2 (Outside the US)  
Condition/Disease:  Systemic Lupus Erythematosus  
 
 
 
Safety Evaluation s:  
The following safety assessments will be evaluated: adverse events , physical examination , clinical laboratory 
tests, pregnancy testing , vital signs ,  and hospital admissions . 
 
 
 
Statistical Methods:  
Analysis  Populations  
 The Modified Intent -to-Treat (mITT) Population will include all randomized subjects who receive at 
least 1 dose of study drug and who contribute any postbaseline efficacy data to the study .  
 The Per-Proto col Population  will include the subset of the mITT population who complete  the study as 
per protocol, have no missing primary endpoint data, and do not have any major protocol deviations .  
 The Safety Popu lation will include all subjects who receive 1 or more doses of study drug . 
Sample Size  
It is expected that approximately 2 70 subjects will be screened to randomize a total of  162 subjects into 1 of 
the 2 treatment groups: 1 mL (80 U) of Acthar every other day  for 4 weeks followed by 1 mL (80 U) of 
Acthar 2 times per week for 20 weeks or 1 mL o f placebo every other day  for 4 weeks followed by 1 mL of 
placebo 2 times per week  for 20 weeks  in a 1:1 ratio ( 81 per group). The primary efficacy analysis will 
compare the SRI response rate in the Acthar  group to the SRI response rate in the placebo grou p. Assuming 2 
subjects might not qualify for the mITT analysis population after randomization, with 80 mITT subjects in 
each treatment group (160 total) and a response rate of 30% in the placebo  group and 55% in the Acthar 
group, the study will have a 90% power to detect a treatment difference at the 0.05 level of significance.   
Statistical Analysis  
The safety analyses will be performed using the safety population. The efficacy  
analyses will be performed using the mITT and per protocol  populations. Analyses performed on the mITT 
population will be considered primary.  
Summaries for continuous variables will include standard statistics (n, mean, SD, median, relevant 
percentiles, minimum, and maximum). Categorical data will be summarized u sing frequency tables that will 
present the subject counts and the percent of subjects falling into that category. All statistical tests will be 2 -
sided with a significance level of 0.05. The statistical analysis plan will describe in further detail the an alyses 
for primary, secondary,  efficacy endpoints.  
Efficacy Analysis  
Subjects will be included in the efficacy analyses based on their treatment assignment. The primary endpoint 
is the proportion of SRI responders at Week 16. The proportio ns of SRI responders for the 2 treatment 
groups will be summarized descriptively by visit and treatment group in tabular format and compared using a 
2-sided Pearson’s chi -square test at a significance level of 0.05. If the responder or non responder count falls 
to equal or below 5 in either treatment group, 2 -sided Fisher’s exact test will be used instead. All quantitative 
secondary and exploratory endpoints will be analyzed using analysis of covariance models with treatment 

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 18 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 Study Title: A Multicenter, Randomized, Double Blind, Placebo Controlled  Study to Assess the Efficacy  
and Safety of  Acthar® Gel in Subjects With Persistently Activ e Systemic  Lupus Erythematosus  Despite 
Moderate Dose Corticosteroids  
Protocol Number: MNK 14304067  Type: Phase 4 (US)/ Phase 2 (Outside the US)  
Condition/Disease:  Systemic Lupus Erythematosus  
group as a facto r and the baseline value of the corresponding endpoint as a covariate. Mixed model with 
repeated measurement s will be performed as deemed necessary. Secondary and exploratory endpoints that 
are proportions will be analyzed using Pearson’s chi -square test o r Fisher’s exact tests.  
 
 
 
 
 
 
 
Safety  Analysis  
Treatment -emergent adverse events  and serious adverse events will be summarized using the MedDRA by 
preferred term within system organ class.  
Hospital admissions and the reason for each admission will be listed and summarized descriptively b y visit 
and treatment.  The cumulative number of hospital admissions will be compared between treatment groups at 
Week 24 with a 2 -sided Pearson’s chi -square test o r Fisher’s exact test at a significance level of 0.05.  
Other safety data will be listed and summarized descriptively or graphically, as appropriate.  
 
 
 
  
 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 19 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 
Screening
(Days -28 to -1)
Randomized Controlled Double-blind Treatment
(24 Weeks)Acthar 1 mL (80 U) QOD x 4 weeks then 2x/week x 20 weeks
PRIMARY ENDPOINT 
(Week 16)PBO Acthar 1 mL QOD x 4 weeks then 2x/week x 20 weeks
Stable steroid dose (7.5 to 30 mg)Attempt steroid 
taperFollow up
(28  5 days) 
8 STUDY SCHEMATIC AND SCHEDULE OF EVENTS  
8.1 Study Schematic  
Figure 8-1: Study Overview  
 
 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 20 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 8.2 Schedule of Study Events  
Table 8-1: Schedule of Study Events  
 
Assessment/Procedure  
Screening  
(Day -28 to Day -1) 
Randomization  
Dosing  Treatment Period  
Follow -up  
Week   0 0 2 (± 3 
days)  4 (± 3 
days)  6 (± 3 
days)  8 (± 3 
days)  12 (± 5 
days)  16 (± 5 
days)  20 (± 5 
days)  24 (± 5 
days) /Early 
Termination  28 (± 5 
days)  
Informed Consent  X            
Inclusion/Exclusion Criteria Review  X X           
Demographics  X            
Medical/Surgical History  X            
Current Medical Condition Review   X  X X X X X X X X X 
Complete Physical Examination  X          X  
Limited Physical Examination   X  X X X X X X X  X 
Height and Weighta  X X  X X X X X X X X X 
Vital Signsb X X  X X X X X X X X X 
12-lead ECG  X          X  
Clinical Laborato ry Testsc  X X  X X X X X X X X X 
Lipid Panel  X X      X   X  
HbA1c  X       X   X  
Serum Pregnancy Test  X          X  
Urine Pregnancy Testd  X     X  X   X 
IGRA for TB  X            
Hepatitis Serologye X            
  X      X   X  
C3, C4 and anti -ds DNA antibodies  X X  X X X X X X X X  
Serology (ANA, ENA)f X            

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 21 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 
 
 Assessment/Procedure  
Screening  
(Day -28 to Day -1) 
Randomization  
Dosing  Treatment Period  
Follow -up  
Week   0 0 2 (± 3 
days)  4 (± 3 
days)  6 (± 3 
days)  8 (± 3 
days)  12 (± 5 
days)  16 (± 5 
days)  20 (± 5 
days)  24 (± 5 
days) /Early 
Termination  28 (± 5 
days)  
  X     X  X  X  
  X     X  X  X  
  X     X  X  X  
SLEDAI -2K X X  X X X X X X X X  
BILAG -2004  X X   X  X X X X X  
PGA   X   X  X X X X X  
SFI     X  X X X X X  
CLASI -Activity   X   X  X X X X X  
28 Joint Count   X   X  X X X X X  
  X     X  X  X  
  X     X  X  X  
Hospital Admissions     X X X X X X X X  
IXRS Contact  X X  X X X X X X X X  
Study Drug and Diary Training   X           
Study Drug Accountability  and Diary Review     X X X X X X X X  
Dispense Study Drug  and Diary   X  X X X X X X X   
Administer First Dose    X          
Adverse Events and Concomitant Treatments  X 
aHeight at screening only.  
bBlood pressure, respiratory rate,  pulse rate  and body temperature . For blood pressure, an average of 3 readings after the subject has been seated for ≥  5 minutes at 
The Screening and Randomization Visits . Single readings after subject has been seated for ≥  5 minutes at all other time points . 
c Chemistry, hematology  assays ,  and u rinalysis  (see Attachment 1 ).  
dPositive urine test after randomization will be confirmed by serum pregnancy test . 
eHepatitis B surface antigen, Hepatitis B core antib ody (HBcAb), hepatitis C virus antibody (HCV Ab), hepatitis C polymerase chain  reaction ([(HCV PCR] for 
subjects positive for HCV Ab only).  
fAutoantibody testing  (ANA , ENA ) may be performed if history is unavailable.  
 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 22 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 9 ETHICAL CONSIDERATIONS  
This clinical study is designed to comply with ICH Guidance  on General Considerations for 
Clinical Trials and applicable national and local regulations.  
9.1 Institutional Review Board /Independent Ethics Committee  
It is the responsibility of the investigator to obtain the approval of the Institutional Review 
Board ( IRB)/Independent Ethics Committee ( IEC) before the start of the study.  The 
investigator will provide Mallinckrodt with a statement of compliance from the IRB/IEC  and/or 
the United States ( US) Department of Health and Human Services general assurance number. 
A copy of the approval letter along with a roster of IRB /IEC  members  and compliance letter  
and/or the US Department of Health and Human Services general assurance number  (if 
applicable)  will be retained as part of the study records . During the course of the  study, the 
investigator  will provide timely and accurate reports to the IRB /IEC  on the progress of the 
study at appropriate intervals (not to exceed 1 year) and at the completion of the study. The 
investigator  will notify the IRB /IEC  of serious adverse ev ents ( SAE ) or other significant 
safety findings  per IRB /IEC  guidelines . The study protocol, informed consent form (ICF), 
advertisements (if any), and amendments (if any) will be approved by the IRB /IEC  in 
conformance with international,  national and local regulatory requirements; and the  Code of 
Federal Regulations  (CFR ), Title 21, Part 56  (where applicable) . 
9.2 Ethical Conduct of the Study  
The study will be conducted in full compliance with applicable international, national and 
local regulatory requirements; US Food and Drug Administration (FDA) regulations  including 
21 CFR 314.106 and 312.120,  (where applicable ); and ICH guidelines for GCP and in 
accordance with the ethical principles that have their origins in the Declaration of Helsinki.  
9.3 Subject Information and Consent  
The ICF must be approved by the sponsor and the IRB /IEC  before any subject  provide s 
consent. The investigator will provide Mallinckrodt with a copy of the IRB/IEC -approved ICF 
and a copy of the IRB/IEC ’s written approval before the start of the study . 
At the Screening Visit , subjects will read the ICF and a Health Insurance Portability and 
Accountability Act (HIPAA) authorization form (if applicable) after being given an 
explan ation of the study. Before signing the ICF and the HIPAA authorization  form (if 
applicable), subject s will have an opportunity to discuss the contents of these forms with study 
site personnel.  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 23 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 Subjects must assent understanding of and voluntarily sign these forms in compliance with 
ICH GCP guidelines and 21  CFR, Parts 50 and 312 (where applicable) , before participating in 
any study -related procedures. Subjects will be made aware that they may wi thdraw from the 
study at any time. Subjects unable to give written informed consent must orally assent to the 
procedures, and written informed consent must be obtained from a legally authorized 
representative in accordance with national  and local laws, as applicable.  
The ICF must contain all applicable elements of informed consent and the mandatory 
statements as defined by national and local regulations including confidentiality.  All versions 
of each subject's signed ICF must be kept on file by the site for possible inspection by 
regulatory authorities and/or authorized Mallinckrodt personnel. Signed copies  of the ICF and 
the HIPAA authorization form, if applicable, will be given to the subject .  
The subject s will be made aware of their right to see and copy their records related to the 
study for as long as the investigator has possession of this information. If the subject  
withdraws consent and/or HIPAA authorization, the investigator can no longer disclose health 
information, unless it is needed to preserve the scientific integrity of the study.  
10 BACKGROUND INFORMATION AND RATIONALE  
10.1 Systemic  Lupus Erythematosus  
Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease characterized by  
excess production of proinflammatory cytokines and formation of autoantibodies  resulting in  
immune complex  deposition , and tissue damage. A range of organ systems may be involved  
(V on Feldt, 1995 ). The frequency of SLE vari es by race and ethnicity, with  higher rates 
reported among black and Hispanics, particul arly women aged 14 to 64 years  (Helmick et al, 
2008 ).  
SLE currently carries an average 10 year survival rate that exceeds  90% (Kasitanon et al, 
2006 ; Trager and Ward, 2001 ). Before 1955, the 5  year survival rate was less than 50%. 
Decreased mortality rates  associated with SLE can be attributed to earlier diagnosis (inc luding 
milder cases),  improvement in disease -specific treatments, and advances in general medical 
care. According to the Centers for Disease Control and Prevention, one third of SLE -related 
deaths in the US occur in patients younger than 45 years, making t his a serious issue despite 
declining overall mortality rates. In 1976, Urowitz first reported bimodal mortality in early v s 
late SLE, noting that SLE -related deaths u sually occur within the first 5 to 10 years of 
symptom onset  (Urowitz, 1976 ). 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 24 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 A number of medications are used in the treatment of SLE  including nonsteroidal anti -
inflammatory drugs (NSAIDs), antimalarials, glucocorticoids, and immunosupp ressive agents. 
In general, low dose g lucocorticoids are used for non organ -threatening disease (cutaneous, 
musculoskeletal, serositis, arthritis, and co nstitutional symptoms) and high dose 
glucocorticoids are reserved for organ threatening disease (eg, cardiopulmonary, hepatic, 
renal, hemolytic anemia, immune thrombocytopenia). Im munosuppressive agents are 
generally reserved for patients with significant organ involvement or patients who have had an 
inadequate response to glucocorticoids. Although  the use of glucocorticoids is common in 
SLE, response to treatment is variable , with  some patients respond ing well to low dose 
therapy and other s requiring  high dose s, although  a minority of patients does  not respond to 
even long courses of high dose therapy  (Petri, 2011 ). While glucocorticoid treatment is 
effective in many cases, side effects are common . 
The primary goal of lupus treatment is to control or halt the inflammatory disease process 
while minimizing side effects. Treatments that reduce or eliminate disease activity without 
adding significant toxi city are needed.  
Belimumab (Benlysta®), a B lymphocyte stimulator  inhibitor, is an SLE targeted therapy 
approved by the  FDA in 2011. It was the first new SLE drug approved in over 50 years. In the 
BLISS 52 Phase 3 study, approximately 58% of Benlysta pati ents (10 mg/kg) responded to 
treatment and 19% were able to decrease prednisone to < 7.5 mg/day  (Navarra et al, 2011 ). 
This is compared to approximately 44% of placebo patients who responded to treatment and 
12% were able to  decrease prednisone to < 7.5 mg/day. Despite the recent approval of 
Benlysta, a significant unmet need remains for treatments that can improve disease activity 
and decrease dependence on chronic prednisone use.  
As described in the Package Insert, Act har® Gel (repository corticotropin  injection, 
hereafter referred to as Acthar)  contains  a highly purified adrenocorticotropic  hormone (ACTH) 
analogue ( Mallinckrodt, 2015 ). It is approved by the FDA for use during an acute exacerbation 
or as maintenance therapy in selected cases of SLE. ACTH is a member of the family of 
structurally related peptides known as melanoco rtin peptides. Melanocortin peptides, which in 
addition to ACTH include α-, β-, and γ-melanoc yte stimulating hormones,  are derived from the 
natural protein pro-opiomelanoco rtin and exert their physiologic effects by binding  to cell 
surface G-prote in coupled receptors known as melanoco rtin receptors (MCR ) (Mountjoy et al, 
1992 ). Five subtypes of MCRs have been  identified to date (MC1 R-MC5 R), each with different 
tissue distributions, binding affinity characteristics, and physiological roles (Getting, 2006 ). 
ACTH binds to  all 5 subtypes of MCR (Schioth et al, 1995 ) and recent experiments 
demonstrate that Acthar also has agonist activity for all 5 MCRs (Mallinckrodt, Unpublished 
Data ). Stimulation of cortisol by ACTH is mediated by activation of the MC2R expressed on 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 25 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 adrenal cortical cells. However, biologic activity of ACTH may extend beyond stimulation of 
adrenal corticosteroid production.  MC1, 3, 4 and 5R are expressed on multiple leukocytes 
subpopulations (eg , T & B cells, macrophages), as well as within target organs (eg , skin, 
kidney, central nervous system [CNS] ) relevant to SLE ( Catania et al, 2004 ).  
Experimental evidence s uggests that MCR ligands such as ACTH and α-MSH may possess 
steroid -independent anti -inflammatory and immune modulatory activity relevant to SLE 
pathophysiology ( Decker  et al, 2014 ; Botte  et al, 2014 ). In a murine model, Acthar  has been 
shown to reduce B -cell differentiation and development, and to decrease circulating auto -
antibodies, proteinuria, renal lymphocyte infiltration and glomerular immune complex 
deposition  (Decker et al, 2014 ).  Similarly, other investigators  demonstrated that alpha -MSH 
attenuated manifestations of pristine -induced lupus in mice ( Botte  et al, 2014 ).  Effects of 
Acthar on human B  cell function were studied in vitro using peripheral blood B cells isolated 
from healthy human subjects . Acthar  dose dependently inhibited interluekin -4/CD40  ligand -
induced B -cell proliferation and immunoglobulin G production without enhancing cell death. 
These data suggest direct effe cts of Acthar on human B -cell function and provide supportive 
evidence for steroid  independent effects of Acthar when used as a treatment for SLE, an 
autoimmune disease characterized  by B -cell activation and humoral autoimmunity ( Olsen et 
al, 2015 ). Historically, ACTH preparations have been used as a treatment  option in SLE, with 
and without corticosteroids (cortisone or prednisone)  (Harris -Jones, 1956 ). 
In a recent publication  (Fiech tner et al, 2014 ), the results of an open  label, single arm study 
supported the use of  Acthar as a treatment for  SLE. A total of 10 female patients with chronic, 
moderate to severe SLE who were receiving a stable dose o f prednisone (or equivalent) ≤ 
 20 mg/day and/or stables doses of azathioprine, antimalarials, mycophenolate 
mofetil/mycophenolic acid, or methotrexate were enrolled. Patients self-administered  a 1 mL 
SC injection daily of Acthar (80 Units [ U]) over 10 day s with an optional 5 day rescue period 
for partial or nonresponders. All patients were assessed weekly from baseline (Day 0) through 
Week 4 (Day 28). There were significant improvements at all follow -up visits in  Systemic 
Lupus Erythematosus Disease Activi ty Index -2000  (SLEDAI -2K) scores and other measures 
of disease activity. These results suggest ed that Acthar may be a therapeutic option for SLE 
patients and may provide significant disease activity reduction.  
The sponsor recently completed a pilot study to explore the effects of Acthar on disease 
activity in SLE  (Furie et al, 2015 ; Becker et al, 2016 ). The study  consisted of 2 treatment 
periods : an 8  week double blind, placebo controlled period followed by an optional 44 week 
open label period , and was performed to examine the effects of Acthar in patients with steroid  
dependent, persistently active SLE with arthritic and/or cutaneous involvement. Subjects 
received 0.5 mL ( 40 U ) SC daily or 1 mL (80 U ) SC every other day of Acthar or volume 

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 26 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 matched  placebo for 4 weeks, followed by dose tapering to 2 times per week (2x/week) during 
Weeks 5 to 8. Subjects who completed the double blind  period were given the option to 
continue into the 44 week  open l abel extension period where all subjects received Acthar. 
From Weeks 9 to 20, Acthar regimen adjustments were permitted based on safety and efficacy 
with a goal of achieving a stable Acthar regimen  by no later than Week 28, which was to be 
maintained for t he remainder of the open label extension.  
The majority of patients in this study were white (63.9%), while 33% were black or African -
American  and 16.7% were of Hispanic or Latino ethnicity. Mean baseline Hybrid Systemic 
Lupus Erythematosus Disease Activity  Index (h SLEDAI) total scores ranged from 8.7 to 11.3 
across treatment groups and mean total British Isles Lupus Assessment Group -2004 ( BILAG -
2004 ) total scores ranged from 13.1 to 18.6.  
A novel responder index that had not been validated was used as the primary endpoint. It was 
defined as the proportion of patients responding to treatment at Week 4, with response defined 
by a decrease in hSLEDAI score from 4  to 0 for arthritis, or from 2  to 0 for rash, with no 
worsening in other organ systems as assessed by BILAG -2004. Although the primary 
endpoint was not met in this pilot study, Acthar was associated with significant improvements 
in several measures of disease activity , including hSLEDAI and BILAG -2004 . The response 
to treatment with Acthar was seen as e arly as Week 6 for improvements from baseline in total 
hSLEDAI score, and by Week 8 significant improvements were seen in the remaining 
measures of disease activity (total BILAG -2004 , improvement in BILAG A and B 
mucocutaneous and musculoskeletal scores, Cutaneous SLE Disease Area and Severity Score 
(CLASI )-Activity, and both tender and s wollen joint c ount). Furthermore, in post hoc 
analyses, the proportion of responders as defined by the SLE Responder Index (SRI), a widely 
accepted and validated composite index  (Furie et al, 2009 ), was significantly higher in the 
combined Acthar group than in the combined Placebo group at Week 8.  
In the open label extension, hSLEDAI, BILAG, and Physician ’s Global Assessment ( PGA ) 
scores general ly decreased over time from Week 8 for both treatment groups (Acthar/Acthar 
and Placebo/Acthar). Subjects randomized to Acthar during the double blind  period who 
continued on Acthar throughout the 44 week open label extension had a durable response to 
therapy, while subjects who crossed over from placebo to Acthar experienced improvements 
in several measures of disease activity during the open label extension .  These improvements 
were generally comparable to the improvements se en with Acthar  treatment from the blinded 
period  of the trial by 12  to16 weeks after Acthar  was initiated.  A notable proportion of 
subjects were able to taper exogenous corticosteroid therapy by Week 52  (Furie et al, 2015 ; 
Becker et al, 2016 ). 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 27 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 In general, Acthar was safe and well tolerated at the doses administered in this pilot study. In 
the double blind period, the most commonly reported treatment -emergent adverse event 
(TEAE) was increased wei ght, for which the incidence in the combined placebo cohort was 
comparable to that in the Acthar 0.5 mL ( 40 U ) and Acthar  1 mL ( 80 U ) cohorts. Two patients 
treated with Acthar had serious TEAEs (moderate viral infection and Klebsiella sepsis), and 4 
patien ts (11.1% overall, 16.0% of the combined Acthar cohort) reported 4 TEAEs leading to 
study drug withdrawal. There were no unexpected adverse events in the open label extension.  
10.2 Product Description  
Acthar is a sterile preparation of a  purified  ACTH analogue formulated in 16% gelatin to provide 
a prolonged release after intramuscular or subcutaneous ( SC) injection. Acthar contains 0.5% 
phenol, not more than 0.1% cysteine (added), sodium hydroxide and/or acetic acid to adjust 
pH, and water for in jection. Acthar is obtained from processing porcine pituitary using a n 
FDA approved process. Acthar is currently labeled for use during an exacerbation or as 
maintenance therapy in selected cases of SLE  (Mallinckrodt, 2015 ). 
Placebo is a sterile preparation of 16% gelatin for intramuscular or SC injection. Placebo 
contains 0.5% phenol, not more than 0.1% cysteine, sodium hydroxide and/or acetic acid to 
adjust pH, and water for injection. The placebo formulation is identical  to Acthar except that it 
contains no active medication.  
10.3 Dosage and Administration  
Investigational medicinal product (IMP) or  study drug  will be used to denote active drug 
(Acthar) and/or volume  match ed placebo . 
Following a screening period of up to 28 days, subjects with persistently active disease SLE 
despite treatment with moderate  dose corticosteroid s will be randomized to receive  either 
Acthar or placebo. Acthar  1 mL  (80 U ) or placebo (1 mL) will be administered as SC doses 
every other day for 4 weeks, followed by Acthar 1 mL (80 U ) or placebo (1 mL) SC doses 
2x/week for an additional 20 weeks.   
10.4 Rationale  
Recent studies ( Fiechtner et al , 2014 ; Furie et al, 2015 ; Becker et al, 2016 ) support the 
efficacy of Acthar as a treatment for SLE.  This study will provide additional  data to support 
the efficacy  and safety  of Acthar in S LE,  
 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 28 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 The Acthar dose and dos ing regimen for this study are based on results from the pilot  Phase 4 
study exploring the efficacy, safety and pharmacodynamics of Acthar in s ubjects with SLE 
and a history of persistently active disease (Furie et al, 2015 ; Becker et al, 2016 ). In that study, 
subjects  received 0.5 mL ( 40 U ) SC daily or 1 mL ( 80 U ) SC every other day  of Acthar or 
volume  matc hed placebo  for 4 weeks, followed by dose tapering to 2x/week  during Weeks 5 
to 8. Subjects who completed the double  blind period  were given the option to continue into 
the 44 week, open label extension period where all subjects re ceived Acthar.  From Weeks 9 to 
20, Acthar regimen adjustments were permitted based on safety and efficacy with a goal of 
achieving a stable Acthar regimen, no later than Week 28, which was to be maintained for the 
remainder of the open label  period . 
The Acthar  dosing regimens studied  during the pilot trial led to clinically meaningful 
improvements in disease activity measures such as hSLEDAI and BILAG -2004 as early as  
8 weeks after initiation of Acthar in the  double blind  period , and  12 to16 weeks after initiating 
Acthar therapy in the open lab el extension . In general, Acthar was safe and well tolerated at 
the doses administered in the double blind and open label extension periods . No unexpected 
adverse events were observed. These results support the effi cacy of Acthar as a treatment 
option in steroid  dependent patients with persistently active SLE .  
10.5 Risks and Benefits  
The common adverse reactions for Acthar are similar to those of corticosteroids and include 
fluid retention , alteration in glucose tolerance, elevation in blood pressure, behavioral and 
mood changes, increased appetite and weight gain.  For a complete reference of known 
potential risk s please refer to the Acthar product labeling (Mallinckrodt , 2015 ). 
SLE is a chronic, autoimmune disease characterized by excess production of autoantibodies, 
immune complex deposition and pro -inflammatory cytokines that can cause inflammation and 
tissue damage in a range of organ systems. Although early diagnosis and advan ces in disease -
specific therapies have improved 5 - to 10 -year survival rates to more than 90% ( Kasitanon et 
al, 2006 ; Trager and Ward, 2001 ), there remain significant unmet needs in the manag ement of 
SLE, particularly among patients with persistent, treatment -refractory disease ( Holloway et al, 
2014 ). Preclinical data ( Decker et al, 2014 ; Olsen  et al,  2015 ) support the potential for Acthar 
to reduce circulating autoantibodies and disease activity.  Additionally, a recently published  
case series ( Fiechtner , 2014 ) and the safety and efficacy data generated from a recently  
completely randomized controlled double blind  pilot study  with an optional open  label 
extension  (Furie et al, 2015 ; Becker et al, 2016 ) support the potential benefits of Acthar  for 
reducing dise ase activity in the patient population to be studied.  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 29 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 11 OBJECTIVES  
11.1 Primar y Objective  
The primary objective of this study is:  
 To determine  the ability  of Acthar  to reduce disease activity as measured by SRI in 
subjects with SLE requiring moderate dose corticosteroids for persistently active 
disease.  
11.2 Secondary  Objective s 
The secondary objectives of this study are:  
 To assess the impact of  Acthar on disease activity , measured by the SLEDAI -2K, 
BILAG -2004 , and P GA, in subjects with SLE requiring moderate dose corticosteroids 
for persistently active disease . 
 To assess the time to response to Acthar in subjects with SLE requiring moderate dose 
corticosteroids for persistently active disease.  
 To further assess t he safety and tolerability of Acthar in subjects with SLE requiring 
moderate dose corticosteroids for persistently active disease.  
11.3 Exploratory Objective s 
  
 
  
  
11.4 Approximate Duration of Subject Participation  
Subjects will participate in the study for a total of up to approximately 32 weeks, including a 
screening  period of up to 28 days , an active treatment period of 24 weeks, and a follow -up 
visit 28 (± 5) days after the last dose of study drug .  
12 STUDY DESIGN  
12.1 Description  
This is a randomized, placebo controlled, double blind study. Following a screening period of 
up to 28 days, subjects with persistently active SLE and moderate to severe rash and/or arthritis 
despite receiving corticosteroids (7.5 mg to 30 mg p er day of prednisone or equivalent) for ≥ 4 
weeks prior to screening , will be randomized in a 1:1 ratio to receive 1 mL (80 U) of Acthar or 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 30 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 matching placebo. At randomization, subjects will be stratified by prednisone equivalent dose 
(≤ 20 mg/day vs >  20 m g/day). During Weeks 1 to 4, 1 mL (80 U) of Acthar or volume 
matched placebo will be administered SC every other day. For the remainder of the study 
(Weeks 5 to 24), Acthar 1 mL (80 U) or volume matched  placebo  will be administered SC 
2x/week. The primary efficacy endpoint is the SRI at Week 16. Corticosteroid taper may be 
attempted and is encouraged between Weeks 16 and 24  if medically appropriate; the taper rate 
and schedule will be at the discretion of the individual investigator . All subjects will have a 
follow -up visit 28 (± 5 ) days after the last dose of study drug.    
12.2 Approximate Duration of Study  
The duration of the study from first subject  first visit to last subject  last visit will be depen dent 
on the ability of the site s to identify and enroll eligible subject s. The entire study is expected 
to require approximately 3 years  to complete.   
12.3 Approximate Number of Subject s 
It is expected that a pproximately 270 subjects will be screened  and 162 subject s will be 
randomiz ed at approximately 60 sites globally . 
13 SELECTION OF SUBJECT S 
13.1 Inclusion Criteria  
Subject s must meet all of the following criteria for inclusion in the study at the Screening 
Visit  and the Randomization Visit . 
1. Subject s must be adequately informed and understand the nature and risks of the study and 
must be able to provide a signature and date on the ICF.  
2. Subjects must  be ≥ 18 years of age at Screening Visit  and can be male or female . 
3. Female subjects must be  of non childbearing potential (hi story of hysterectomy, bilateral 
oophorectomy, or bilateral tubal ligation; or postmenopaus al with no history of menstrual  
flow in the 12 months prior to the Screening Visit); or if of childbearing potential must be  
nonpregnant,  nonlactating and agree to use effective contraception  when with a male 
partner  throughout study participation (through the Follow -up Visit) . Acceptable forms of 
contraception include hormonal measures (oral contraceptive pills, contraceptive patch, 
contra ceptive ring, injections), intrauterine device s, double barrier method (condom plus 
diaphragm, condom or diaphragm plus  spermicidal gel or foam) , and abstinence .  
4. Male subjects with a female partner of childbearing potential must have been surgically 
sterilized (vasectomy) or agree to use a double barrier for contraception (condom plus 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 31 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 diaphragm, condom or diaphragm plus spermicidal gel or foam)  or remain abstinent  
throughout their study participation  (through the Follow -up Visit) . 
5. Subjects  must  have a diag nosis of SLE according to the American College of Rheumatology  
revised criteria (fulfilled  ≥ 4 criteria)  (Hochberg, 1997 ; Tan et al, 1982 ). 
6. Subjects must have active SLE as demonstrated by a SLEDAI -2K score of  ≥ 6 at the 
Screening Visit and a clinical SLEDAI (excluding laboratory results) score ≥ 4 at the 
Screening  and Randomization  Visits . Points for arthritis and /or rash  must be present at both  
the Screening and Randomization  Visits . 
7. Subjec ts must have moderate to severe rash and/or arthritis  as demonstrated by  BILAG -2004  
score A or B in the in the mucocutaneous and/or musculoskeletal body systems  at both 
Screening  and Randomization Visits . 
8. A documented history o f positive antinuclear antibody (ANA)  
OR 
A screening result of positive ANA test by immunofluorescent assay (IFA) with titer ≥ 
1:80 or an equivalent assay  
OR  
A documented history or positive screening result of elevated anti-dsDNA or ENA 
antibodies (e.g ., anti-Smith , SSA, SSB , RNP ). 
9. Subjects  must have been on prednisone (or prednisone equivalent) for ≥ 8 weeks prior to the 
Screening Visit and on a stable dose of 7.5 mg to  30 mg  of prednisone (or prednisone 
equiva lent) for ≥ 4 weeks prior to the Screening  Visit. 
10. Subjects must have a mean systolic blood pressure ≤ 150 mm Hg and a diastolic blood 
pressure  of ≤ 90 mm Hg determined by the average of 3 seated readings taken at least 5 
minutes apart at the Screening  and Randomization Visit s. 
11. Subjects using  antimalarials and NSAIDs must have  been on a stable dose for at least 4 
weeks prior to the Screening Visit and remain on that dose throughout the study.  
12. Subjects using methotrexate, azathioprine and/or mycophenolate mofetil must have been a 
stable dose for  at least 8 weeks  prior to the Screening Visit and remain on that dose 
throughout the study.  
13. Subject s must be able to communicate effectively with study personnel.  
14. Subject s must be able and willing to follow all protocol requirements and study 
restrictions . 
15. Subject s must be able and willing to return for all  study visits . 
 

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 32 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
  
13.2 Exclusion Criteria  
Subject s are ineligible for study participation if they meet any of the following criteria at the 
Screening Visit or the Randomization Visit . 
1. Subject  is from a vulnerable population, as defined by the US CFR  Title 45, Part 46, 
Section 46.111(b)  and other local and national regulations , including but not limited to , 
employees (temporary, part -time, full time, etc) or a family member of the research staf f 
conducting the study, or of the sponsor , or of the clinical research organization, or of the 
IRB/IEC. 
2. Subject is unwilling to receive , or is intolerant of , SC injections.  
3. Subject has a history of  sensitivity to ACTH preparations (including but not limite d to 
Acthar and Synacthen) . 
4. Subject has a history of sensitivity to porcine protein products.  
5. Subject  has severe active lupus nephritis defined as serum creatinine > 2.5 mg/ dL or 
protein creatinine ratio  > 1.5 g/g,  or subject has required hemodialysis  within 3 months 
prior to the screening visit or  is likely to require hemodialysis  throughout the study . 
6. Subject has active CNS manifestations of lupus (as evidenced by seizures, psychoses , 
organic brain syndrome, cerebrovascular accident, cerebritis, or C NS vasculitis) within the 
3 months pri or to the Screening Visit or de velops CNS lupus between the Screening Visit 
and the first dose of study drug 
7. Subject  has Type 1 or Type 2 diabetes mellitus or is taking  hypoglycemic medication (a 
history of gestational  diabetes mellitus is not exclusionary).  Subjects must not have 
glycosylated hemoglobin (HbA1c)   6.5 at the Screening Visit.  
8. Subject has received any steroid injection (intramuscular, intraarticular or intravenous  
[IV]) within 4 weeks  prior to the Screeni ng Visit  (use of topical and/or inhaled steroids is 
not exclusionary).  
9. Subject has received oral prednisone  > 30 mg per day or equivalent, cyclosporine, or any 
nonbiologic investigational drug within 3 months prior to the Screening Visit . 
10. Subject has recei ved IV  immunoglobulin (Ig)  or plasmapheresis within 4 months prior to 
the Screening Visit . 

Acthar® Gel (Repository Corticotropin Injection)  
Clinical Protocol MNK14 304067  
Revision Date:  01 June 2017  Page 33 of 75 
CONFIDENTIAL  
PROPRIETARY  Mallinckrodt  11.Subject has received cyclophosphamide , abatacept , B cell targeted therapy  (anti-CD-22
[epratuzumab ] or belimumab ), B cell depleting therapy (rituximab or other anti-CD20
agent, or anti -CD52 agent [alemtuzumab]) , or any biologic investigational agent within 6
months prior to the Screening Visit .
12.Subject has any known  contraindication (s) to Acthar ( Mallinckrodt , 2015 ) including , but
not limited to:
Any known history of scleroderma, osteoporosis, or ocular herpes simplex.  For the
purposes of this study, osteoporosis is defined as evidence of vertebral or long bone
fracture, or lumbar T -score >  2.0 SD below the mean of the reference population.
Any primary adrenocortical insufficiency, or adrenal cortical hyperfunction.
Any current congestive heart failure ( defined as New York Heart Association
Functional Class III to IV).
Peptic ulcer (within  24 weeks  prior to the Screening Visit ).
Recent major surgery ( within  24 weeks  prior to the Screening Visit ).
13.Subject has a history o f chronic active hepatitis including  active or chronic hepatitis B,  or
acute or chronic hepatitis C.  Subjects must have negative Hepatitis B surface antigen
(HBsAg)  or Hepatitis B core antibody (HBcAb)  and negative Hepatitis C virus antibody
(HCV) or HCV polymerase chain reaction (PCR) <  25 IU/mL  (HCV PCR will be
automatically analyzed if HCV is positive ) at the Screening Visit.
14.Subject has a h istory of tuberculosis (TB) infection , any signs/symptoms of TB , or any
close contact with an individual with an active TB infectio n.  Subjects must not have a
positive or indeterminate interferon gamma release assa y (IGRA) for TB at the Screening
Visit.
15.Subject has a  clinically significant infection requiring  administration of IV antibiotics or
hospitalization in the 4  weeks prior to the Screening Visit  or between the Screening Visit
and the first dose of study drug .
16.Subject has k nown immune compromised status  (not related to SLE or therapies for SLE) ,
including but not limited to , individuals who have undergone organ transplantation or who
are known to be positive  for the human  immunodeficiency virus .
17.Subject has any s olid tumor malignanc y currently diagnosed or undergoing therapy, or has
received therapy for any solid tumor malignancy  in the 5 years prior to the Screening Visit;
with the exception of treated and cured bas al cell carcinoma, treated and cured squamous
cell carcinoma of the skin, and treated and cured carcinoma in situ of the cervix.

Acthar® Gel (Repository Corticotropin Injection)  
Clinical Protocol MNK14 304067  
Revision Date:  01 June 2017  Page 34 of 75 
CONFIDENTIAL  
PROPRIETARY  Mallinckrodt  18.Subject has a  diagnosis of, is undergoing therapy for, or has received therapy for a
hematologic malignancy  in the 5 years prior to the Screening Visit.
19.Subject has current or recent (within 24 weeks  prior to  the Screening Visit ) drug or alcohol
abuse as defined in Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition,
Diagnostic Criteria for Drug and Alcohol Abuse  (American Psychiatric  Association,
2013 ). 
20.Subject has a ny of the following laboratory abnormalities  at the Screening Visit :
Hemoglobin ≤ 8.0 g/dL.
Platelets ≤ 50,000 cells/ μL.
Absolute neutrophil count (ANC) ≤ 1000 cells/ μL.
Aspartate  aminotransferase  (AST), alanine  aminotransferase  (ALT), or total bilirubin
 2 times upper limit of normal (ULN).
21.Subject has any other clinically significant disease , disorder or laboratory abnormality
(including those listed on the Prescribing Information Section 5 : Warnings  and
Precautions [Mall inckrodt , 2015 ]) which, in the opinion of the investigator (by its nature
or by being inadequately controlled), might put the patient at risk due to participation  in
the study, or may influence the results of the study or the subject ’s ability to complete the
study.
13.3 Screen  Failure  
Subjects will be allowed to repeat any single screening assessment/ procedure once , if necessary, 
if it is within the screening window. The subject will not be considered a screen failure unless 
the repeat assessment/procedure results do not meet eligibility criteria.  The period from starting 
screening related procedures at the Scree ning Visit to the Randomization Visit  must not 
exceed 28 days, inclusive of any repeat screening procedures.   
Subjects who do not meet all of the eligibility criteria at the Screening or Randomization 
Visits will be deemed a screen failure and the reason for the screen failure will be 
documented.  A subject who i s a screen failure  at the Screening or Randomization Visit may be 
rescreened. The subject must repeat all screening procedures.  The period from the start of 
rescreening related procedures to the first dose of study drug must not exceed 28 days.  
Subjects ma y be rescreened only once.  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 35 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 14 PRIOR AND CONCOMITANT MEDICATION S/TREATMENTS  
The start and stop date, dose, unit,  frequency, route of administration, and indication for all 
prior  (taken within the 30 days prior to the Screening Visit ) and concomitant  (taken from the 
Screening Visit t hrough  the Follow -up Visit)  medications and nondrug therapies  (eg, blood 
transfusions, oxygen supplementation) received  will be recorded .  
In addition, a ll prior treatments for SLE will be recorded with start and stop date , dose, unit, 
frequency and route of administration.  
14.1 Permitted Concomitant  Medications  
The use of antimalarials and NSAIDs  is permitted provided the subject has been on a stable 
dose for at least 4 weeks prior to the Screening Visit and will remain on that dose throughout 
the study.  
The use of methotrexate, azathioprine and mycophenolate mofetil is permitted provided the 
subject has been on a stable dose for at least 8 weeks  prior to the Screening Visit and will 
remain on that dose throughout the study.  
The use of topical and/or inhaled  corticosteroids is allowed during the study.  
14.2 Prohibited Concomitant Medications  
The following treatments will not be permitted during the study:  
 Administration of l ive or live -attenuated vaccines.  
 Oral prednisone (or equivalent) > 30 mg/day . 
 Steroid inject ions (intramuscular, intraarticular, or IV).  
 IV Ig or plasmapheresis.  
 Cyclosporine . 
 Cyclophosphamide . 
 Abatacept . 
 B cell targeted therapy, anti -CD-22 (epratuzumab)  or belimumab.  
 B cell depleting therapy (rituximab or other anti -CD20  agent, or anti -CD52 agent 
[alemtuzumab]).  
 Any other new immunosuppressant therapy or any other new treatmen t for SLE 
(initiated after the Screening Visit).  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 36 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
  Any investigational drug, device, or procedure administered as part of a research study.  
If any prohibited medication is taken during the study, all pertinent information will be 
recorded  in source document s and the electronic case report form ( eCRF ). The designated 
study medical monitor ( MM) must be informed immediately so the sponsor may determine 
whether to continue the subject  in the study.  
15 PROCEDURES  
The detailed schedule  of study procedures  is summarized  in the Schedule of Study Events  
(Table 8-1). What follows is a general outline of required procedures and a suggested order for 
completion.  
15.1 Screening Visit  (Study Days -28 to -1) Procedures  
Screening  assess ments must  be perfor med within 1 to 28 days prior to the Week 0 Visit .  
The following  procedures  will be perfor med at the Screening Visit : 
 Informed consent.  
 Inclusion/exclusion criteria.  
 SLEDAI -2K and BILAG -2004 . 
 Medical and surgical history , including the first day of the last menstrual period for 
women of childbearing potential . 
 Demographics . 
 Complete p hysical examination.  
 Height and Weight.   
 Vital signs . 
 12-lead electrocardiogram (ECG).  
 Clinical laboratory tests  (chemistry , hematology , and urinalysis) . 
 Lipid panel.  
 HbA1c . 
 Serum pregnancy test .  
 Hepatitis serology .  
 IGRA test  for TB .  

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 37 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
  C3, C4 and anti -ds DNA antibodies . 
 Serology (ANA, ENA; if history is unavailable)  
 Contact the Interactive Phone/Web Response System (IXRS).  
 Adverse event s and concomitant medications . 
 
Subjects will be allowed to repeat any screening procedure  once , if necessary, if it is within 
the screening window.  
15.2 Randomization  Visit  (Week 0) and First Dose Procedures  
All evaluations will occur prior to the first dose of study drug , except as noted . 
 Inclusion/exclusion criteria review . 
  
  
 28 Joint Count, SLEDAI -2K, B ILAG -2004, PGA, and CLASI  -Activity . 
 Current medical condition  review.  
 Limited physical examination.  
 Weight.  
 Vital signs . 
 Clinical laboratory tests .  
 Lipid panel.  
 Urine pregnancy test.  
 C3, C4, and anti -ds DNA antibodies.  
   
   
  
   
 Subject diary  and study drug  administration  training.  
 Contact IXRS and  dispense study drug  kits. 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 38 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
  Study drug  administration  under supervision of study staff  and observation for at least 
1 hour thereafter .  
 Adverse event s and concomitant medications.  
15.3 Week 2 (± 3 days) and 6  (± 3 days) Procedures  
 SLEDAI -2K.   
 Current medical condition  review.  
 Limited physical examination.  
 Weight.  
 Vital signs . 
 Clinical laboratory tests   
  
 C3, C4, and anti -ds DNA antibodies.  
 Hospital admissions . 
 Subject diary review . 
 Study drug accountability.  
 Contact IXRS and  dispense study drug  kits.  
 Adverse events and concomitant medications.  
15.4 Week  4 (± 3 days) and 20  (± 5 days)  Procedures  
 28 Joint Count, SLEDAI -2K, B ILAG -2004, PGA, CLASI - Activity , and Safety of 
Estrogens in Lupus Erythematosus National Assessment (SELENA) Flare Index (SFI).  
 Current m edical condition  review.  
 Limited physical examination.  
 Weight.  
 Vital Signs.  
 Clinical laboratory tests .  
 C3, C4, and anti -ds DNA antibodies . 
 Hospital admissions . 
 Subject diary review . 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 39 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
  Study drug accountability.  
 Contact IXRS and  dispense study drug  kits.  
 Adverse events and concomitant medications.  
15.5 Week  8 (± 3 days) and 16  (± 5 days) Procedures  
  
  
 28 Joint Count, SLEDAI -2K, BILAG -2004, PGA,  CLASI -Activity , and SFI . 
 Current medical condition  review.  
 Limited physical examination.  
 Weight.  
 Vital Signs.  
 Clinical laboratory tests .  
 Urine pregnancy test.  
 C3, C4 and anti -DS DNA antibodies.  
   
   
 Serum cortisol and aldosterone.  
 Hospital admissions.  
 Subject diary review . 
 Study drug accountability.  
 Contact IXRS and  dispense study drug  kits.  
 Adverse events and concomitant medications.  
15.6 Week  12 (± 5 days)  Procedures  
 28 Joint Count, SLEDAI -2K, B ILAG -2004, PGA, CLASI -Activity , and SFI . 
 Current medical condition  review.  
 Limited physical examination.  
 Weight.  

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 40 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
  Vital Signs.  
 Clinical laboratory tests .  
 Lipid panel.  
 C3, C4 and anti -DS DNA antibodies . 
 HbA1c.  
  
 Hospital admissions.  
 Subject diary review . 
 Study drug accountability.  
 Contact IXRS and  dispense study drug  kits.  
 Adverse events and concomitant medications.  
15.7 Week 24  (± 5 days) /Early Termination Procedures  
  
  
 28 Joint Count, SLEDAI -2K, B ILAG -2004, PGA,  CLASI -Activity , and SFI.  
 Current medical condition  review.  
 Complete  physical examination.  
 Weight.  
 Vital Signs.  
 12-lead ECG.  
 Clinical laboratory tests .  
 Lipid panel.  
 Serum  pregnancy test.  
 HbA1c.  
  
 C3, C4 and anti -DS DNA antibodies . 
   

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 41 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
    
  
 Hospital admissions.  
 Subject diary review . 
 Study drug accountability.  
 Contact IXRS  
 Adverse events and concomitant medications.  
 
15.8 Follow -up Visit  - Week 28  (± 5 days) 
The following procedures will be completed at  the follow -up visit 28 (± 5) days after the final 
dose of study drug : 
 Current medical condition review.  
 Limited physical examination.  
 Weight . 
 Vital signs . 
 Clinical laboratory tests . 
 Urine pregnancy test. 
 Adverse events and concomitant medications.  
16 INVESTIGATIONAL MEDICINAL PRODUCT  (Study Drug)  
16.1 Methods of Assigning Subject s to Treatment Groups  
16.1.1  Randomization and St ratification  
Subjects will be randomized according to computer -generated allocation scheme to receive 
either Acthar 1 mL (80 U) or placebo 1 mL administered every other day for 4 weeks f ollowed 
by 2x/week for 20 weeks. The randomization will be stratified by  location (US or outside the 
US) and prednisone equivalent dose (≤ 20 and  > 20 mg/day). For each stratum, a separate 
randomization scheme will be produced. Both investigators and the s ubjects will be blinded to 
the treatment assignment. A block randomization will be performed. The biostatistician will 
decide on the details at the time of the creation of the randomization scheme.  

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 42 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 16.1.2  IXRS  
The investigator or designee will contact IXRS to register subjects at screening . The subject ’s 
identification  (ID) number will be determined by the IXRS and will be used to identify the 
subject s for the duration of the study within all systems and documentatio n. Subject 
identification numbers will consist of 7 digits: the first 4 digits reflect the site number 
assigned to the Investigator and the last 3 digits are the subject number.  
A subject ID number will not be assigned to more than 1 subject. If a subject is not eligible to 
receive treatment, or should a subject discontinue from the study, the subject ID number 
cannot be reassigned to another subject.  
In the event that a subject is rescreened, they do not need a new subject ID number.  At the 
Randomization V isit, qualified subjects who meet all of  the eligibility criteria will be 
randomized into the study.   
The investigator or designee must contact the IXRS to report a subject as a screen failure if 
the subject does not meet eligibility criteria prior to rand omization . 
The investigator or designee must contact IXRS to record each subject visit, to  receive the 
study drug  assignment s, and to report any subject status changes . 
The investigator  must maintain a subject  master log linking the subject  ID to the subject ’s 
name. The investigator  must follow all applicable privacy laws in order to protect a subject ’s 
privacy and confidentiality. Information that could identify a subject  will be masked on 
material received by the sponsor.  
16.2 Emergency Identification of Investigational Medicinal Product  
In case of an emergency  during the Randomized Treatment  Period , when knowledge of the 
investigational product assignment is required for the medical management of an individual 
subject , the investigator may obtain the trea tment assignment of the subject  experiencing the 
emergency. The treatment blind for that subject  may be broken by accessing the I XRS using 
instructions  provided  by the IXRS vendor . The investigator must notify the sponsor ’s MM or 
physician designee immedia tely after determining that it is necessary to unblind the treatment 
assignment. The investigator and sponsor should make every effort to document and limit the 
people who are unblinded to the subject ’s treatment assignment. The investigator must also 
indicate in source documents that the blind was broken and provide the date, time, and reason 
for breaking the blind.  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 43 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 16.3 Dosing Procedures  
Both Acthar and the placebo are  supplied as 5 mL multidose vial s. Acthar vials contain  80 U of 
ACTH per mL. The vial s should not be over  pressurized prior to withdrawing the product. The 
vials s hould be warmed to room temperature before using and will be labeled according to all 
applicable national and local regulations.  
The following treatments will be administered:  
 Acthar  1 mL ( 80 U) SC doses every other day for 4 weeks, followed by 1 mL ( 80 U) 
SC 2x/week for an additional 20 weeks.  
 Placebo  (1 mL) SC doses every other day for 4 weeks, followed  by 1 mL SC  2x/week 
for an additional 20 weeks.  
The subject or subject ’s caregiver will administer the first dose of Acthar in the clinic under 
the supervision of study staff.  The subject will remain in the clinic for at least 1 hour postdose 
to monitor for allerg ic or anaphylactic reactions . Thereafter,  all doses will be adminis tered by 
the subject or the subject ’s caregiver at home.  
16.3.1  Treatment Discontinuation  
Treatment with study drug should be discontinued if any of the following occur:  
 Development of accelerated hypertension  (defined as systolic blood pressure ≥ 180 and 
diastolic blood pressure ≥ 100 mm Hg) that cannot be managed by the adjustment of 
concomitant medications such as antihypertensive medications . 
 Development of congestive heart failure (Class III or IV) that cannot be managed by 
the adjustment of concomitan t medications such as diuretics and antihypertensive 
medications . 
 Development of diabetic signs/symptoms (ie, HbA1c > 6.5, or fasting plasma glucose 
> 126 mg/dL, or classic symptoms of hyperglycemia with random plasma glucose 
> 200 mg/dL) that cannot be ma naged by the adjustment of concomitant medications 
such as insulin and oral hypoglycemic agents .  
 Development of any other adverse event ( AE) of at least moderate intensity and 
possibly, probably or definitely related to study drug that cannot be managed b y the 
adjustment of concomitant medications.  
Missed doses of study drugshould be discussed with the medical monitor.  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 44 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 16.4 Storage of Clinical Supplies  
Acthar and placebo  will be maintained in a temperature controlled , secure  locked area with 
restricted access  at the study site .  
Study drug will  be supplied in kits containing the appropriate amount of vials . Study drug  will 
be stored  under refrigeration between 2° to  8°C (36° to  46°F).  Please refer to the Pharmacy 
Manual for complete information regarding storage and accountability of study drug . 
16.5 Drug Accountability  
In accordance with ICH requirements, the investigator  will, at all times, be able to account for 
all study drug  furnished to the study site. A drug accountability record will be maintained for 
this purpose. The investigator  must maintain accurate records indicating dates and quantity of 
study drug  received, to whom it was dispensed ( subject -by-subject  accounting) and accounts 
of any study drug  accidentally or deliberately destroyed. All unused study drug  not involved 
in immediate subject  dosing will be maintained under locked , temperature -controlled  storage 
at the study site.  
16.6 Compliance  Monitoring  
Prior to beginning the administration of study drug , subjects and/or their caregiver will be 
trained on dosing administration and must exhibit proper technique. Subjects and/or their 
caregiver will be trained on the completion of the study diary and will complete  study diary 
entries to record all study dru g administration and will bring it , along with all study drug  kits 
including used vials to each visit. Each time study drug  is dispensed compliance will be 
encouraged. Subject diary training is an ongoing process as the  diary will be reviewed with 
the subj ect at each visit to monitor compliance with study drug  administration.  
17 EFFICACY  ASSESSMENTS  AND PROCEDURES  
Efficacy  assessments will be evaluated  at times specified in the Schedule of Study Events 
(Table 8-1). Below is a general instruction of the administration of these assessments. Specific 
instructions and questionnaires /forms (where appropria te) will be provided in a separate 
document.  
17.1 Physician Completed Assessments  
The SLEDAI -2K, BILAG -2004,  PGA,  SFI, CLASI -Activity  and 28 Joint Count  are 
assessments  to be completed by the investigator or designee. When th ese assessment sare 
required, they should be the done immediately after subject re ported outcome/ questionnaire 
completion (if applicable)  and must be completed prior to any study drug dosing.  

. Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 45 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 17.1.1  Systemic Lupus Erythematosus Disease A ctivity Index -2000  
The SLEDA I-2K is a modified version of a composite score based on the presence or absence  
of clinical signs, clinical symptoms , and immunologic  laboratory results taken within 10 days 
of the evaluations  (Bombardier et al, 1992 ; Gladman et al, 2002 ). Disease  activity is based on 
24 questions weighted across 9 organ systems with total scores ranging from 0 to 105 but are 
generally <  20 with very active disease. The Clinical SLEDAI -2K score is derived without the 
inclusion of points attributed to laboratory test results.  
17.1.2  British Isles Lupus Assessment Group 200 4  
The BILAG scores disease involvement within each organ system based upon the intent to 
treat premise  (Isenberg et al,  2005 ). The major difference between the BILAG and  other 
disease activity indices is that disease activity in different organs/systems  is reported 
separately. Specific manifestations in 9 organ systems are scored  (there are a total of 97 
items ). Each item is rated as 0 (not present), 1 (improving), 2 (same), 3  (worse), or 4 (new ) in 
the last 4 weeks compared with the previous 4 weeks.  
The numerical scores are used to categorize each organ system by an alphabetical score: ‘A’ 
reflecting severe disease requiring increases in prednisone to > 20 mg daily and/or addition of 
immunosupp ressive agents, ‘B’ indicated less active disease , requiring low -dose prednisone 
and/or symptomatic treatment with NSAIDs and/or antimalarials, ‘C’ reflecting mild disease 
requiring only symptomatic therapy, ‘D’ reflecting previous organ system involvement  
without current disease activity, and ‘E’ reflecting no prior or no current disease involvement 
in that organ system.  
BILAG 2004  is a revised version of the original BILAG. The revised index removed the 
vasculitis section, placing individual clinical fea tures more appropriately within the other 
organs or systems. It now incorporates sections on gastrointestinal disease and has an 
ophthalmology section, both missing from the original. Furthermore, some items related to 
damage were removed.  
17.1.3  Physicians Globa l Assessment  
PGA is a 100 mm visual analogue scale a nchored at 0 (none) and 3 (severe) with intermediate 
lines at 1 (mild) and 2 (moderate).  It was designed for physicians to provide an overall 
assessment of a patient ’s wellbeing  (Petri et al, 1999 ). 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 46 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 17.1.4  SELENA Flare Index  
The SFI categorizes SLE flare as mild, moderate or severe based on the following 6 variables 
(Buyon et al, 2005 ): 
 Change in SELENA SLEDAI score from the most recent assessment to current.  
 Change in signs or symptoms of disease activity.  
 Change in prednisone dosage.  
 Use of new medication for disease activity or hospitalization.   
 Change in PGA score.  
 Hospitalization  for SLE activity.  
A severe flare is defined as 1 or more of the following: a) SLEDAI score greater than 12; b) 
new or worsening CNS  involvement, vasculitis, glomerulonephritis, myositis, 
thrombocytopenia (platelet count <  60,000/mL), or hemolytic anemia ( hemoglobin level  
< 70 g/L or decrease in hemoglobin level >  30 g/L), each requiring doubling of corticosteroid 
dosage to a final dosage > 0.5 mg/kg per day or acute hospitalization; c) any manifestation 
requiring an increase in dosage of prednisone or equ ivalent drug to greater than 0.5 mg/kg per 
day, or initiation of therapy with cyclophosphamide, azathioprine, mycophenolate mofetil, or 
methotrexate; d) hospitalization for lupus activity; and e) PGA  score  greater than 2.5  points . 
17.1.5  Cutaneous Lupus Erythema tosus Disease Area and Severity Score - 
Activity  
The CLASI was  developed to specifically track  cutaneous activity and damage  in SLE ( Klein 
et al, 2010 ). The CLASI uses separate activity and damage scores as indicators of disease 
burden. The activity score reflects ongoing inflammation that can be treated , with points given 
for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and 
inflammatory alopecia. The damage s core represents the irreversible  aftermath of 
inflammation . Only the  CLASI activity score will be us ed in the study.  
17.1.6  28 Joint Count  
The 28 Joint Count includes assessment of swelling and tenderness in the shoulders, elbows, 
wrists, metacarpophalangeal joints, proximal interphalangeal joints and knees.  
17.2 SLE Responder Index  
An SRI responder is defined as a subject with a 4 point reductio n from baseline in SLEDAI -
2K, with no new BILAG A and no more than 1 new BILAG B organ domain score s compared 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 47 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 with baseline, and no worsening in PGA (≤ 10% increase from baseline)  (Furie et al, 2009 ). 
This index will be calcul ated by the sponsor.  
 
 
 
 
 
 
  
 
  
  
  
  
  
  
  
  
  
  
   
   
  
  
  
 
 
  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 48 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
   
  
  
  
  
 
 
 
 
  
19 SAFETY ASSESSMENTS AND PROCEDURES  
The following safety assessments will be evaluated: AEs, p hysical examinations, clinical 
laboratory test results (chemistry, lipid panel, hematology, and urinalysis ), HbA1c, vital signs , 
 medical history, weight, concurrent medical conditions, and 
hospital admissions. All safety ass essments will be performed at times outlined in the 
Schedule of Study Events ( Table 8-1). Additional (unscheduled) safety assessments may be 
performed as needed.  
19.1 Adverse Events  
Adverse events will be recorded from signing of the ICF and followed by the investigator 
until the AE is resolved or stabilized. Any and all safety measures (which includes standard of 
care activities) should be provided by the study site to the subject.  Any study site follow -up 
should be documented.  
Refer  to Section 21 for additional details on the handling of AEs and SAEs.  
19.2 Medical and Surgical History  
Medical and surgical history will be obtained at the Screening  Visit. Medical history will 
include a review of the following systems: general, dermatological, respirat ory, 
cardiovascular, gastrointestinal, genitourinary, gynecological, endocrine, musculoskeletal, 
hematological, neuropsychological, immune (allergies), and head, eyes, ears, nose, and throat. 
Historical and current medical conditions including date of last  menstrual period for female 
subjects will be recorded.  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 49 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 19.3 Current Medical Conditions  
At each visit after screening, subjects will be asked about any changes in medical conditions, 
specifically new medical conditions and worsening of existing medical conditi ons. Any 
changes since the Screening Visit  will be recorded as AEs, as appropriate.  
19.4 Physical Examination  
A complete physical examination will be performed at the Screening and Week 24/Early 
Termination Visit . The complete physical examination includes eva luation of the head, eyes, 
ears, nose, throat, neck (including thyroid), cardiovascular system (including assessment of 
heart, peripheral pulses, presence or absence of edema), lungs, abdomen (including liver and 
spleen, bowel sounds), lymph nodes, musculo skeletal system (including spine, joints, 
muscles) neurological system (including cranial nerves, reflexes, sensation, strength), skin, 
extremities and other conditions of note.  
A limited physical examination, including evaluation of lungs, heart, abdomen,  and 
extremities will be done at all other visits.  
The findings of the physical examinations completed prior to the Randomization visit  will be 
recorded as Medical Hi story ..  
19.5 Height and Weight  
Height will be collected at screening only. Weight will be collected at all visits.  
19.6 Vital Signs  
Vital signs will be obtained after the subject has been seated for 5 minutes (minimum) and 
will include systolic and diastolic blood pressures, pulse rate, respiratory rate, and body 
temperature . Additionally, at  the Screening and Randomization Visits , blood pressure will be 
measured 3 times, with at least 5 minutes between assessments after the subject has been 
seated for a minimum of 5 minutes prior to the initial blood pressure assessment.  
The investigator may perform additional unscheduled vital sign measurements to evaluate or 
manage a suspected AE. These unscheduled vital sign measurements should be obtained after 
the subject has been seated for at least 5 minutes, if possible. Unscheduled vital signs will be  
recorded.   
The date and time for all vital sign  assessments  will be recorded.    

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 50 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 Screening /Randomization   
A subject with  systolic blood pressure  150 mm Hg and diastolic blood pressure  90 mm Hg 
(average of 3 assessments) at the Screening or Randomizatio n Visits does not qualify for the 
study.  
On Study Assessments  
If an on -study  systolic blood pressure  is  150 mm Hg and diastolic blood pressure  is 
 90 mm Hg , an AE will be recorded  if the investigator determines the change is clinically 
significant or requires a change in the subject ’s clinical management.  
19.7 Clinical Laboratory Tests (Chemi stry, Hematology and Urinalysis ), 
HbA1c, IGRA, Direct Coombs test , Pregnancy Tests ,  
; and C3, C4, and anti -ds DNA antibodies  
The clinical laboratory tests are listed in Attachment  1. All clinical laboratory tests will be 
done at a central laboratory facility except urine pregna ncy (at the site) and  
 Specific instructions for collection, processing, storage, and shipment 
of clinical laboratory samples will be provided in a separate laboratory manual, where 
appropriate.  
Samples for laboratory testing at all visits may be collected under fasted or nonfasted 
conditions.  Fasting early morning samples are preferred, but a random daytime sample is 
acceptable. The date and time of the sample collection must be documented on the laboratory 
report. Investigators must review and sign laboratory reports. The clinical significance of each 
laboratory abnormality will be documented. New clinically significant laboratory 
abnormalities or clinically significant changes in laboratory values will be reported as AEs.  
Hematology  with differential , serum chemistry,   and urinalysis samples will be collected at the 
specific times starting at screening and throughout the study . 
In addition:  
 All female subjects of child -bearing potential will have a serum pregnancy test  at the  
Screening and Follow -up Visits. A positive urine test after randomization will be 
confirmed by a serum pregnancy test . Urine pregnancy test s will be done at other 
specified  visits throughout the study.  Results must be available prior to dosing with 
protocol mandated study drug . Subjects with positive results will be ineligible for 
study entry ( Screening Visit or Randomization)  or withdrawn from the study.  Any 

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 51 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 female subject that becomes pregnant during t he study will be immediately withdrawn 
and the pregnancy reported as per Section 21.6 . 
If applicable, the subject ’s agreement to use contraception  throughout their study 
participation, and for 28 days after ending st udy participation, will be documented . 
 A lipid panel (high density lipoprotein, low density lipoprotein, triglycerides, and total 
cholesterol) will be done at the Screening, Randomization, Week 12, and Week 24 
Visits.  
 HBsAg and HBcAb  will be performed at t he Screening Visit. Results of these tests 
must be negative or nonreactive for subjects to qualify for the study.   
 HCV will be performed at the Screening Visit.  A positive HCV will automatically 
trigger a HCV PCR analysis.  HCV PCR must be < 25 IU/mL  to qua lify for the study.  
 IGRA  for TB will be performed at the S creening Visit. Results of this test must be 
negative for subjects to qualify for the study.  
 HbA1c will be performed at the Screening Visit. HbA1c must be ≤ 6.5% for subjects 
to qualify for the stu dy. Additional HbA1c tests will be done at specified times during 
the protocol.  
  
 
 C3, C 4, and anti -ds DNA antibody samples will be taken at specified times during the 
study.  
Out-of-Range Laboratory Values  
Laboratory values from samples collected at the Screening Visit  will be evaluated by the 
investigator for eligibility of the subject in th e study. Clinical laboratory tests may be repeated 
once to determine subject eligibility.  
Laboratory values that fall outside the reference range from samples collected at the 
Randomization Visit and throughout the study will be assessed by the investigato r for clinical 
significance. If the out of range value is deemed clinically significant by the investigator, an 
AE will be recorded.  

. Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 52 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 19.8 Hospital Admissions  
The number of hospital admissions and the reason for each admission will be collected at 
specified times in the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
21 STATISTICAL METHODS AND PLANNED ANALYSIS  
21.1 General Considerations  
This section provides a general description  of the statistical methods to be used in analyzing 
both safety and efficacy data. The key statistical issues or considerations will be addressed.  
 
 
Unless otherwise specified, all statistical tests will be two -sided with a significance level of 
0.05. Summary statistics will be provided for all study variables with descriptive statistics 
(number of observations, mean, SD, median, mi nimum, and maximum) for numerical (or 
continuous) variables.  Frequency and percentages will be calculated for categorical variables.  

. Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 53 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 All data will be summarized by treatment groups as appropriate. Data summary and analyses 
will be performed with SAS 9. 2 or higher . 
21.2 Analysis Populations  
 The Modified Intent -to-Treat (mITT) Population will include all randomized subjects 
who receive at least 1 dose of study drug and who contribute any postbaseline  efficacy 
data to the study .  
 The Per-Proto col Population will include the subset of the mITT population who 
complete  the study as per protocol, have no missing primary endpoint data, and do not 
have any major protocol deviations .  
 The Safety Popu lation will include all subjects who receive 1 or more doses of study 
drug. 
The safety analyses will be performed using the safety populations. The efficacy and 
pharmacodynamic analyses will be performed using the mITT and Per Protocol populations ; 
analyses performed on the mITT population will be considered primary.  
21.3 Efficacy Endpoints  
21.3.1  Primary  Efficacy  Endpoint  
The primary efficacy endpoint will be proportion of re sponders as assessed by SRI at 
Week 16. 
21.3.2  Secondary  Efficacy Endpoints  
 Change from baseline  over time  in SLEDAI -2K (Week 0 to 16) .  
 Time to first response as assessed by SRI. 
 Change from baseline over time in total BILAG -2004 (Week 0 to 16) .  
 Change from baseline  over time  in PGA  (Week 0 to 16).   
 Proportion of subjects with decrease from baseline of ≥ 4 points in SLEDAI -2K over 
time (Week 0 to 16) .  
 Change from baseline in  CLASI -Activity score over time  (Week 0 to 16)  in subjects 
with CLASI -Activity at baseline . 
 Change from baseline  (Week 0 to 16) in 28 Joint Count (tender and swollen)  in subjects 
with tender and swollen joints at baseline . 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 54 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 21.3.3  Exploratory Endpoints  
  
  
  
 
  
  
 
  
  
  
  
   
  
 
  
  
21.4 Safety  Endpoints  
 Summary of general safety profile, including adverse events (seriou s and non -serious), 
vital signs and laboratory assessments by study period and over the entire study.  
21.5 Subject  Characteristics  
21.5.1  Demographics  
The demographic information will be summarized for each analysis population by treatment 
group . 
21.5.2  Medical and Surgical History  
Prior medical conditions or procedures will be summarized by body system and treatment 
group.  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 55 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 21.5.3  Prior and Concomitant Medications  
Prior and concomitant medications will be  coded according to the WHO Drug Dictionary. The 
incidence (number and percent)  of prior and concomitant medication use will be summarized 
by treatment group.   
21.5.4  Subject  Disposition and Exposure to Study Drug  
Subject disposition will be summarized . The number of subject s who complete the study and 
who do not complete the study  along wi th the reasons  for discontinuation from the study  will 
be summarized.   
21.6 Efficacy Analysis  
Subjects will be included in the efficacy analyses based on their treatment assignment. The 
primary endpoint is the proportion of SRI responders at Week 16. The propor tions of SRI 
responders for the 2 treatment groups will be summarized descriptively by visit and treatment 
group in tabular format and compared using a 2 -sided Pearson ’s chi-square test at a 
significance level of 0.05. I f the respo nder or non responder coun t falls to equal or below 5 in 
either treatment group, 2 -sided Fisher ’s exact test will be used instead. All quantitative 
secondary and exploratory endpoints will be analyzed using analysis of covariance models 
with treatment group as a factor and the base line value of the corresponding endpoint as a 
covariate.  Mixed model with repeated measurement will be performed as deemed necessary .  
Secondary and exploratory endpoints that are proportions will be analyzed using Pearson ’s 
chi-square test or Fisher ’s exact tests.  
For the primary efficacy endpoint, subjects who do not provide data to allow classification as 
responders will be considere d nonresponders, that is, missing data will be imputed as non -
responder . A similar approach will be applied to secondary efficacy  endpoints that are 
proportions; missing will be classified as not  satisfying the conditions described for that 
endpoint.  A ful l description of missing data imputation method for all endpoints will be 
described in the statistical analysis plan.  
 
 
 
 
 
 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 56 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
  
 
21.8 Safety Analysis  
All subject s who receive at least 1 dose of study drug w ill be included in the safety analyses.  
21.8.1  Adverse Events  
Adverse events will be coded using MedDRA (version 19.0 or higher) by preferred term 
within system organ class. The number of AEs and the number of su bjects reporting AEs will 
be listed and summarized descriptively by body system, preferred term, severity, and causality 
for each treatment group.  Only TEAEs (events that are new in onset or aggravated in severity 
following treatment) will be included in all summaries . SAEs (including death) will be 
summarized.   
21.8.2  Clinical Laboratory Tests;  and C3, C4, and 
anti-ds DNA Antibodies  
Clinical laboratory tests (hematology, lipid panel, blood chemistry, and u rinalysis );  
 and C3, C4, and anti -ds DNA antibodies  results will be  listed by subject and  
summarized by visit and treatment group. Categorical laboratory results will be presented with 
the frequency and percentage in each category by treatment group. Change from  baseline at 
each visit will also be summarized. Shift tables will be generated if applicable. Select 
laboratory parameters may be presented graphically. Abnormal lab oratory  values will be 
identified and analyzed.  
21.8.3  Vital Signs  
Vital sign results (heart rat e, diastolic/systolic blood pressures, respiratory rate, and body 
temperature) and corresponding changes from baseline values will be summarized  at each 
visit with descriptive statistics by treatment group.   
21.8.4  Hospital Admissions  
Hospital admissions and the reason for each admission will be listed and summarized 
descriptively by visit and treatment. The cumulative number of hospital admissions will be 
compared between treatment groups at Week 24 with a 2 -sided Pearson ’s chi-square test or 
Fisher ’s exact test at a significance level of 0.05. 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 57 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 21.8.5  Other Safety Analysis  
Other safety assessments including physical examinations, weight, pregnancy testing, and 
HbA1c will be listed and summarized descriptively or graphically, as appropriate.  
 
 
 
 
  
21.10  Interim Analysis  
Blinded aggregate data analyses will be completed when 25%, 50% and 75% of subjects 
complete Week 16.  No other interim analyses are planned for this study.  
21.11  Statistical Power and Sample Size Considerations  
It is expected that approximately 270 subjects will be screened to randomize a total of  162 
subjects into 1 of the 2 treatment groups: 1 mL (80 U) of Acthar every other day  for 4 weeks 
followed by 1 mL (80 U) of Acthar for 20 weeks or 1 mL o f placebo every other day  for 4 
weeks followed by 1 mL of placebo 2 times per week for 20 weeks in a 1:1 ratio (81 per 
group). The primary efficacy analysis will compare the SRI response rate in the Acthar 1 m L 
(80 U) group to the SRI response rate in the placebo group. Assuming 2 subjects might not 
qualify for the mITT analysis population after randomization, with 80 mITT subjects in each 
treatment group (160 total) and a response rate of 30% in the placebo  group and 55% in the 
Acthar group, the study will  have a 90% power to detect a treatment difference at the 0.05 
level of significance.   
21.12  Deviations From Statistical Analysis Plan  
Any deviations from the planned statistical analysis will be described and justified in the final 
clinical study report as appr opriate.  
22 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  
22.1 Safety  
For safety information about Acthar  refer to the most recent version of the Prescribing 
Information ( Mallinckrodt, 2015 ) and the Investigat ors Brochure ( Mallinckrodt, 2016 ).  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 58 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 22.2 Definitions  
Adverse Event  
An AE is any untoward or undesirable medical occurrence in a subject  who is administered 
IMP, which does not necessarily have to have a causal relationship with this trea tment.  
Examples of AEs include but are not limited to:  
 Clinically significant laboratory findings . 
 Clinically significant changes in physical examination findings . 
 An AE occurring due to IMP overdose whether accidental or intentional . 
 An AE occurring from IMP abuse . 
 An AE associated with IMP withdrawal . 
 Unexpected Adverse Event. 
An unexpected AE is defined as an AE, the nature and severity of which is not consistent with 
the applicable product information in the most recent version of the Investigator ’s Brochure.  
SLE Activity Changes  
All changes in SLE activity that are unequivocally due to progression of disease should not be 
reported as an AE unless they result in a SAE as define d below.  
Serious Adverse Event  
An SAE is defined as any untoward medical o ccurrence that at any dose results in any of the 
following outcomes:  
 Death . 
 A life -threatening AE . 
 Inpatient  hospitalization or prolongation of existing hospitalization . 
 A persistent or significant incapacity or substantial disruption of the ability to con duct 
normal life functions . 
 Results in a congenital anomaly/birth defect . 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 59 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, 
may je opardize the subject  or subject  and may require medical or surgical intervention to 
prevent one of the outcomes listed above. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency department  or at home,  blood 
dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of 
drug dependency or drug abuse.  
Death  
Death is an outcome of an event. The event that resulted in death should be recorded  and 
reported on the SAE Form. All causes of death must be reported as SAEs. The investigator 
should make every effort to obtain and send death certificates and autopsy reports to 
Mallinckrodt.  
Life-Threatening Event  
A life -threatening event refers to immediate risk of death as the ev ent occurred per the 
reporter. A life -threatening event does not include an event that, had it occurred in a more 
severe form, might have caused death but, as it actually occurred, did not create an immediate 
risk of death. For example, hepatitis that reso lved without evidence of hepatic failure would 
not be considered life -threatening, even though hepatitis of a more severe nature can be fatal. 
Similarly, an allergic reaction resulting in angioedema of the face would not be life -
threatening, even though an gioedema of the larynx, allergic bronchospasm, or anaphylaxis can 
be fatal.  
Hospitalization  
Hospitalization is defined as an official admission to a hospital. Hospitalization or 
prolongation of a hospitalization constitutes a criterion for an AE to be ser ious; however, it is 
not in itself considered an SAE. In absence of an AE, a hospitalization or prolongation of a 
hospitalization should not be reported by the investigator as an SAE. S uch s ituations include, 
but are not limited to, the following:  
A hospit alization or prolongation of hospitalization is needed for a procedure required by the 
protocol.  
A hospitalization or prolongation of hospitalization is part of a routine procedure followed by 
the center (eg, stent removal after surgery). This should be re corded in the study file.  

. Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 60 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 A hospitalization for a preexisting condition that has not worsened.  
Note that t he following hospitalizations are not considered SAEs in Mallinckrodt clinical 
studies:  
A visit to the emergency department  or other hospital departm ent of less than 24 hours that 
does not result in admission (unless considered "important medical event" or life -threatening 
event).  
22.3 Adverse Event and Serious Adverse Event Classifications  
Study Drug  Relatedness  
The following classifications should be used when evaluating the relationship of AEs or SAEs 
to study treatment ( Table 22-1). 
Table 22-1:  Adverse Event Relationships  
Relationship  Definition  
Not Related  No relationship between the experience and the administration of  study treatment; 
related to other etiologies such as concomitant medications or subject ’s clinical state.  
Unlikely Related  The current state of knowledge indicates that a relationship is unlikely.  
Possibly Related  A reaction that follows a plausible tem poral sequence from administration of the study 
treatment and follows a known response pattern to the suspected study treatment. The 
reaction might have been produced by the subject ’s clinical state or other modes of 
therapy administered to the subject . 
Related  A reaction that follows a plausible temporal sequence from administration of the study 
treatment and follows a known response pattern to the suspected study treatment and 
can be confirmed with a positive re -challenge test or supporting laboratory da ta. 
 
Severity Assessment  
For purposes of consistency, if required the investigator may use the intensity grades 
presented in  Table 22-2. 
Table 22-2:  Adverse Event Severity Grades  
Grade  Definition  
Mild  Does not interfere with subject 's usual function and activities  
Moderate  Interferes to some extent with subject 's usual function and activities  
Severe  Interferes significantly with subject 's usual function and activities  
 

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 61 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 If an AE increases in severity (eg, from moderate to severe); decreases in severity (eg, 
changes from moderate to mild); or there is a change in seriousness, a new AE will be opened 
and the original AE will be closed. If an AE is still ongoing at the time of a subject ’s 
completion of the follow -up visit, the resolution/stop date and time is left blank.  
To ensure there is no confusion or misunderstanding of the difference between the terms 
“serious ” and “severe, ” which are not synonymous, the following note  of clarification is 
provided:  
The term “severe ” is used to describe the intensity (severity) of a specific event (as in mild, 
moderate, or severe myocardial infarction); the event itself, however, may be of relatively 
minor medical importance (such as a s evere headache). This is not the same as “serious, ” 
which is based on the subject /event outcome or action criteria usually associated with events 
that pose a threat to a subject 's life or functioning. Seriousness (not severity) serves as a guide 
for defini ng regulatory reporting obligations.  
22.4 Adverse Event and Serious Adverse Event Recording and Reporting  
AEs and SAEs will be recorded  from signing of the ICF through completion of the Follow -up 
Visit. The investigator is required to record  the AE or SAE regardless of the severity of the 
event or  its relationship to study treatment.  The investigator must follow up on all AEs and 
SAEs reported to have occurred through the Follow -up Visit  until the even t has resolved  or 
stabilized or at such t ime the investigator  refers the subject  to a nonstudy physician. The 
investigator will document the further follow -up information in the subject ’s source 
document.   
During the period specified above, the investigator will:  
 Record all AEs and SAEs  from the signing of the ICF  through the completion of  the 
Follow -up Visit . 
 Report all SAEs on an SAE Report Form to Global Pharmacovigilance . 
 Report all pregnancies to Global  Pharmacovigilance on the Pregnancy Surveillance 
Form . 
 Submit any Expedited Safety Report or Suspected Unexpected Serious Adverse 
Reaction  from Global Pharmacovigilance  to the IRB /IEC . 
The reporting requirements for AEs are summarized in Table 22-3. 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 62 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 Table 22-3: Reporting Requirements for Adverse Events  
Seriousness  Reporting Time  Type of Report  
All Serious  Within 24 hours of first knowledge of 
event  Initial report on the SAE Form,  appropriate 
eCRF, and source document  
Within 24 hours of receipt of follow -up 
information  Follow up report on the SAE Form,  appropriate 
eCRF, and source document  
Nonserious  Per case report form submission 
procedure  Appropriate eCRF and source document  
 
Adverse Events  
Adverse events can be reported spontaneously or elicited during open -ended questioning ( ie, 
"How have you been feeling since your last visit?"), examinati on, or evaluation of a subject . 
Signs and symptoms must be recorded using standard medical terminology. For subject s 
incapable of giving consent, the legally acceptable representative may provide information 
regarding the subject ’s status.  
All fields on the AE CRF page should be complet ed for each event with a full description of 
the event and date of onset/start and resolution/stop. A medical diagnosis if known, should be 
recorded in lieu of each individual sign and symptom associated with the diagnosis and 
experienced by the subject . If no medical diagnosis is known, the term used by the subject  to 
describe the event or signs noted by the site personnel should be recorded.  
Serious Adverse Events  
Initial Reporting  
Serious adverse event s (based on FDA/ICH definition of an SAE) require immediate reporting 
to Global Pharmacovigilance .  
 For all SAEs, the investigator, or designee, must complete the SAE Report Form with 
the minimum information required by FDA and ICH and fax it to Mallinckro dt at 
+1 314-654-5759 or email at PVClinical@ mallinckrodt.com  within 24 hours of first 
knowledge of the event even if the experience  does not appear to be related to the IMP. 
 The investigator , or designee , will receive acknowledgement of receipt of the SAE  
Report Form from Mallinckrodt.  
 Should the investigator or designee have any difficulty in sending the SAE Report, 
they may contact Mallinckrodt contacts listed i n Section 2.2 . 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 63 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
  If there is any doubt about whether the  information constitutes an SAE, the 
information is to be treated as an SAE.  
The investigator(s) or designee is required to submit the any Expedited Safety Report or 
Suspected Unexpected Serious Adverse Reaction to the responsible IRB/ IEC. 
The sponsor will ensure that  any Expedited Safety Report or Suspected Unexpected Serious 
Adverse Reaction  are submitted to the FDA  and other regulatory agencies  as appropriate . 
Follow Up Reporting  
The investigator or designee must complete an SAE Report F orm for all follow -up 
information received and fax  or e-mail it to Mallinckrodt at +1  314-654-5759  or 
PVClinical@ mallinckrodt.com  within 24 hours  of receipt. The investigator(s) or designee will 
receive acknowledgement of receipt for each SAE Report Form f rom Mallinckrodt.  
 The investigator or designee is required to provide all related information/supporting 
documentation of an SAE until the SAE  is resolved  or stabilized or  the subject  has 
been referred to a nonstudy physician  for follow -up treatment .  
The investigator(s) or designee is required to submit the Safety Alert to the responsible 
IRB/ IEC.  
The sponsor will ensure that  any Expedited Safety Report or Suspected Unexpected Serious 
Adverse Reaction  are submitted to the FDA and other regulatory agencies  as appropriate . 
22.5 Adverse Events of Special Interest  
AEs of special interest for this study are outlined below. Adverse events of special interest 
will be followed until resolution or return to baseline.   
 Elevated blood pressure  (defined as systolic blood p ressure ≥ 180 and diastolic blood 
pressure ≥ 100 mm Hg).  
 Hyperglycemia  (HbA1c > 6.5%, or fasting plasma glucose > 126 mg/dL, or classic 
symptoms of hyperglycemia with random plasma glucose >  200 mg/dL) . 
 MedDRA System Organ Class infection/infestation that are considered SAEs or lead to 
treatment disconti nuation . 
 Hy’s Law cases (ALT > 3 x ULN, with total bilirubin > 2 x ULN,  no initial signs of 
cholestasis [alkaline phosphatase within the reference range], and no other reason can 
be found to explain liver in jury).   

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 64 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 22.6 Pregnancy Reporting  
Certain information, although not considered an SAE, must be recorded, reported, and 
followed up as indicated.  This includes the following:  
Pregnancy exposure to an investigational medicinal product, except for exposure to prenatal 
vitamins. Subject s should not become pregnant during the study. If the subject  becomes 
pregnant, study treatment must be discontinued immediately. The investigator must report the 
pregnancy by submitting the appropr iate form to Global Pharmacovigilance  (fax at 
+1 314-654-5759 or ema il at PVClinical@ mallinckrodt.com ) within 24 hours of confirmation 
of a pregnancy (ie, positive serum pregnancy test result) . The outcome of pregnancy (eg, 
spontaneous abortion, live birth , still birth, congenital anomalies, birth defects) must be 
reported by submitting the appropriate form to Global  Pharmacovigilance  (fax at +1  314-654-
5759 or ema il at PVClinical@ mallinckrodt.com  ) within 24 hours of the pregnancy outcome 
being submitted t o the study site . If the pregnancy results in a live birth, a post delivery follow -
up will be performed at least 28 days after the baby is born  and must be reported to Global 
Pharmacovigilance (fax at +1  314-654-5759 or ema il at PVClinical@ mallinckrodt.com ) 
within 24  hours  of the study site becoming aware of the follow -up information . Both maternal 
and paternal investigational medicinal product exposures are collected.  
If the female partner of a male subject becomes pregnant during the study, the site will 
forward the Pregnancy Notification form and the Pregnancy Report Fax cover page to Global  
Pharmacovigilance  (fax at +1  314-654-5759 or ema il at PVClinical@ mallinckrodt .com ), 
within 24 hours of being notified.  The outcome of pregnancy (eg, spontaneous abortion, live 
birth, still birth, congenital anomalies, birth defects) must be reported by submitting the 
appropriate form to Global  Pharmacovigilance (fax at +1  314-654-5759 or ema il at 
PVClinical@ mallinckrodt.com  ) within 24 hours of the pregnancy outcome being submitted 
to the study site. If the pregnancy results in a live birth, a postdelivery follow -up will be 
performed at least 28 days after the baby is born and must be reported to Mallinckrodt 
Pharmacovigilance (fax at +1  314-654-5759 or ema il atPVClinical@ mallinckrodt.com  ) 
within 24  hours of the study site becoming aware of the follow -up information.  
23 SUBJECT  DISCONTINUATION OR WITHDRAWAL  
23.1 Subject  Withdrawal  
Subject s who discontinue, or are withdrawn from the study for any reason, will be considered 
early termination . All subjects  who terminate early will be required to have the Early 
Termination  safety assessments ( see Section 14.7 ) to assess their continued well-being.  

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 65 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 The reason for discontinuation will be recorded . A subject  may be discontinued from the study 
for the following medical or administrat ive reasons:  
Withdrawal by Subject  
Subject s will be free to discontin ue from the study at any time. Subject s who have received at 
least 1 dose of  study drug  but do not complete the study will not be replaced.  
Adverse E vent 
If a dosed subject  suffers an AE that, in the judgment of the investigator , sponsor or MM, 
presents an unacceptable consequence or risk to the subject , the subject  will be discontinued 
from  study drug . In addition, subjects who experience any of the adverse events described in 
Section 15.3.1  will be discontinued.  
Death  
In the event that a subject  dies during the study, death will be the reason for discontinuation.  
Lost to Follow -up 
Every effort should be used to maintain contact with subjects during their participation in the 
study. A subject m ay be considered lost to follow -up if the there is no response to 3 attempts 
to reach the subject by telephone and no response to a certified letter sent to the last known 
address of the subject.  Efforts to contact the subject should be noted in source doc umentation.  
Met Withdrawal Criteria  
If a subject  develops a condition that meets any of the exclusion criteria (Section 13.2) or fails 
to meet an inclusion criteria (Section 13.1) during the study that is not  considered to be an AE 
or is noncompliant (eg, has a positive pregnancy), the subject  will be discontinued from study 
drug. Discontinuation from study drug is also mandated for safety and/or tolerability issues as 
outlined in Section 15.3.1 ). 
Worsening of Disease Activity  
Subjects may be withdrawn i f, in the opinion of the investigator, there is a lack of efficacy 
during the study.   

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 66 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 Other  
If the above reasons are not applicable, please use the “Other ” option and provide the 
appropriate reason for subject  withdrawal.  
24 STUDY SUSPENSION, TERMINATION, AND COMPLETION  
The sponsor may suspend or terminate the study or part of the study at any time for any 
reason. If the investigator  suspends or terminates the study, the investigator  will promptly 
inform the sponsor and the IRB /IEC  and provide them with a detailed written explanation. 
Upon study completion, the investigator  will provide the sponsor, IRB/IEC , and regulatory 
agency with final reports and summaries as required by regulations. Study termination and 
follow -up will be performed in compliance with Mallinckrodt standard operating procedures.  
25 PROTOCOL AMENDMENTS  
Any change in the study plan r equires a protocol amendment. A n investigator  must not make 
any changes to the study without IRB /IEC  and sponsor approval except when necessary to 
eliminate apparent immediate hazards to the subject s. A protocol change intended to eliminate 
an apparent imm ediate hazard to subject s may be implemented immediately, but the change 
must then be documented in an amendment, reported to the IRB /IEC  within 5 working days, 
and submitted to the appropriate regulatory agency in the required time frame.  
26 QUALITY CONTROL  AND ASSURANCE  
The sponsor performs quality control and assurance checks on all clinical studies that it 
sponsors. Before enrolling any subject s in this study, sponsor personnel and the investigator  
review the protocol, the IB, the eCRFs and instructions for their completion, the procedure for 
obtaining informed consent, and the procedure for reporting AEs and SAEs. A qualified 
representative of the sponsor will monitor the conduct of the study. Duri ng these study site 
visits, information recorded in the eCRFs will be verified against source documents.  
26.1 Study and Study Site Discontinuation Criteria  
The sponsor , investigator , or local and national regulatory authorities  may discover conditions 
during th e study that indicate that the study or study site should be terminated. This action 
may be taken after appropriate consultation between the sponsor and investigator . Conditions 
that may warrant termination of the study/ study site include, but are not limi ted to:  
 The discovery of an unexpected, serious, or unacceptable risk to the subject s enrolled 
in the study.  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 67 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
  The decision on the part of the sponsor to suspend or discontinue testing or evaluation 
of the IMP. 
 Failure of the investigator  to enroll subject s into the study at an acceptable rate.  
 Failure of the investigator  to comply with pertinent regulations.  
 Submission of knowingly false information from the study site to the sponsor , study 
monitor , or local and national regulatory authorities . 
 Insufficient adherence to protocol requirements .  
 Study/ study site termination and follow -up will be performed in co mpliance with 
Mallinckrodt standard operating procedures . 
27 DIRECT ACCESS, DATA HANDLING, AND RECORD -KEEPING  
27.1 Investigator  
The investigator  will permit study -related monitoring, audits, IRB /IEC  review, and regulatory 
inspections by providing direct access to original source data and documents.  
All subject  information will b e recorded on source documents. The eCRFs must be fully 
completed and include all required data for all subject s randomized . All eCRF data must be 
submitted to the sponsor throughout and at the end of the study.   
If an investigator  retires, relocates, or otherwise withdraws from conducting the study, the 
investigator  must no tify the sponsor to agree upon an acceptable storage solution. Regulatory 
agencies will be notified with the appropriate documentation.  
Any significant changes in study personnel will require an updated Statement of Investigator 
(ie, FDA form 1572) to be f iled with the sponsor.  
The investigator  must notify their IRB /IEC  of protocol deviations in accordance with local 
regulatory and IRB /IEC  requirements.  
27.2 Sponsor  
The eCRF data are stored in a database and processed electronically. The sponsor ’s MM 
reviews the  data for safety information. The data are reviewed for completeness, and logical 
consistency. Automated validation programs will identify missing data, out -of-range data, and 
other data inconsistencies. Clinical laboratory data will be processed electroni cally. Requests 
for data clarification are forwarded to the study  site for resolution.  

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 68 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 28 SUBJECT  INJURY  
In general, subject  to specific provisions in the clinical trial agreement, if a subject  is injured 
as a direct result of an investigational medicinal product, the sponsor will pay for reasonable 
and necessary medical treatment for the injury, to the extent that such expenses are not 
covered by the subject ’s medical insurance, a government program, or other responsible third 
party. If laws or regulations of  the locality in which the study is taking place require additional 
payment of expenses, the sponsor shall comply with such laws or regulations. Where 
applicable, the sponsor has taken specific national insurance.  
29 RECORDS RETENTION  
The investigator  shall r etain and preserve 1 copy of all data collected or databases generated 
in the course of the study, specifically including but not limited to those defined by GCP as 
essential. Essential documents should be retained until at least 2  years after the last app roval 
of a marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational medici nal product. These 
documents should be retained for a longer period, however, if required by the applicable 
regulatory requirements or by an agreement with the sponsor. It is the responsibility of the 
sponsor to inform the investigator /institution as to wh en these documents no longer need to be 
retained. Prior to destruction of any study essential documents, the investigator  must first 
obtain written approval from the sponsor.  
 
 
 
 
 
 
 
  
31 PUBLICATION POLICY  
31.1 Sponsor ’s Publication Policy  
The sponsor ’s policy is to publish or otherwise communicate the results of its hypothesis -
testing clinical studies, regardless of outcome, for marketed products, compound(s) or 
product(s) being investigated that are later approved for marketing. Hypothesis -testing clinical 

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 69 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 studies are those studies intended to provide meaningful results by examining prestated 
questions using predefined statistically valid plans for data analysis, thereby providing firm 
evidence of safety and/or efficacy to support product c laims.  
Exploratory studies, in contrast, serve to set direction for possible future studies. They have 
significant statistical limitations, provide only preliminary information about a disease, 
condition, or product, and are not designed to provide final c onclusions on product claims. 
The sponsor does not commit to publish or otherwise communicate the results of every 
exploratory study, because this information is of an exploratory nature and often highly 
proprietary. However, if information from an explora tory study is of significant medical 
importance, the sponsor will publish or otherwise communicate the results.  
The sponsor ’s decision to publish or otherwise publicly communicate the results of this study 
will be made in accordance with all applicable law s, regulations, and sponsor policies 
regarding publication and communication of clinical study results.  
31.2 Investigator ’s Ability to Publish  
Terms and provisions of publication rights are governed by the Publication Section in the 
clinical trial agreement.  
  

. Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 70 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 32 REFERENCES  
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders  (5th 
Edition). 2013 . Washington, DC.  
Becker, P.; Furie, R.; Mitrane, M.; Zhao, E.  Repository Corticotropin Injections (RCI) 
Attenuates Disease Activity in Patients with Persistently Active Systemic Lupus 
Erythematosus (SLE) Requiring Corticosteroids: Results From a 44 Week Open -Label 
Extension Study.  To be presented at the 2016 Annual  Congress of Rheumatology; June 2016 ; 
London, England.  
Bombardier, C.; Gladman, D.D.; Urowitz, M.B.; Caron, C.; Chang, C.H. Description of the 
SLED AI: A Disease Act ivity Index for Lupus Patients. The Committee on Prognosis Studies 
in SLE. Arthritis R heum. 1992 , 35, 630 -640. 
Botte, D.A.C.; Noronha, I.L.; Malheiros, D.M.A.C.; Peixoto, T.V .; de Mello, S.B.V . Alpha -
melanocyte Stimulating Hormone Ameliorates Disease Activity in Induced Murine Lupus -like 
Model. Clin. Exp. Immun.  2014 , 177, 381 -390. 
Buyon, J.P.; P etri, M.A.; Kim, M.Y .; Kaluniam, K.C.; Grossman, J.; Hahn, B.H.; et al. The 
Effect of Combined Estrogen and Progesterone  Hormone Replacement Therapy on Disease  
Activity in SLE: A Randomized Trial.  Ann. Internal Med.  2005 , 142, 953 -962. 
Catania, A.; Gatti, S.; Colombo, G.; Lipton, J.M. Targeting Melanocortin Receptors as a 
Novel Strategy to Control Inflammation. Pharmacol. Rev.  2004 , 56, 1 -29. 
Decker, D.; Grant, C.; Oh, L.; Becker, P.; Young, D.; Jordan, S. Immunomodulatory Effects of 
H. P. Acthar Gel on B Cell Development in the NZB/W F1 Mouse Model of Systemic Lupus 
Erythematosus. Lupus , 2014 , 23, 802 -12. 
Fiechtner, J.J.; Montroy, T. Treatment of Moderately to Severely Active Systemic Lupus 
Erythematosus With Adrenocorticotropic Hormone:  A Single -site, Open -label Trial. Lupus . 
2014 , 23, 905 -12. 
Furie, R.A.; Das, M.; Li, D.; Smythe, S.; Mathura, E.; Becker, P. Repository Corticotropin 
Injections (H.P. Acthar® Gel) Attenuates Disease Activity in Patients With Persistently Active 
Systemic Lu pus Erythematosus (SLE) Requiring Corticosteroids,  Arthritis Rheumatol.  2015 , 
67, S10.  

 Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 71 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 Furie, R.A.; Petri, M.A.; Wallace, D.J.; Ginzler E.M.; Merrill, J.T.; Stohl, W.; et al. Novel 
Evidence -Based Systemic Lupus Erythematosus Responder Index. Arthritis Rhe um. 2009 , 61, 
1143 -1151.  
Getting, S.J. Targeting Melanocortin Receptors as Potential N ovel Therapeutics. Pharmacol. 
Ther . 2006 , 111, 1 -15. 
Gladman, D.D.; Ibanez, D.; Urowitz, M.B. Systemic Lupus Erythematosus Disease Activity 
Index 2000. J. Rhe umatol . 2002 , 29, 288 -291. 
Gordon, C.; Isenberg, D.; Lerstrom, K.; Norton, Y .; Enkeleida, N.; Pushparajah, D.S. The 
Substantial Burden of Systemic Lupus Erythematosus on the Productivity and  Careers of 
Patients: a European Patient -driven Online Survey. Rheumato l. 2013 , 52, 2292 -2301.  
Harris -Jones, J.N. The role of ACTH and Cortisone in the Treatment of Systemic Lupus 
Erythematosus. Postgrad. Med. J.  1956 , 32, 145 -149. 
Helmick, C.G.; Felson , D.T. ; Lawrence, R.C.; Gabriel, S. ; Hirsh, R.; Kwoh, C. K .; et al. 
Estimates of the Prevalence of Arthritis and Other Rheumatic Conditions in the United States. 
Part I. Arthritis Rheum . 2008 ; 58, 15 -25. 
Hochberg, M.C. Updating the American College of Rheumatology Revised Criteria for the 
Classification of Systemic Lupus Erythematosus . Arthritis Rheum.  1997 , 40, 1725.  
Holloway, L.; Humphrey, L.; Heron, L.; Pilling, C.; Kitchen, H.;  Hojbjerre, L.; et al. Patient -
reported Outcome Measures for Systemic Lupus Erythematosus Clinical Trials: A Review of 
Content Validity, Face Validity , and Psychometric Performance. Health Qual. Life Outcomes.  
2014 , 12, 116.  
Isenberg, D. A.; Rahman, A.; Allen E.; Farwell, V .; Akl, M.; Bruce, I.M. BILAG 2004. 
Development and Initial  Validation of the British  Isles Lupus Assessment Group ’s Disease 
Activit y Index for Patients with Systemic Lupus Erythematosus . Rheumatol . 2005 , 44, 902 -
906. 
Jolly, M.; Pickard, A.S.; Wilke, C.; Mikolaitis, R.A.; Teh, L -S.; McElhine, K.; et al. Lupus -
specific Health Outcomes Measure for US Patients: The Lupus QOL. -US Version. Ann. 
Rheum. Dis.  2010 , 69, 29 -33. 
Kasitanon, N.; Magder, L.S.; Petri, M. Predictors of Survival in Systemic Lupus 
Erythematosus. Medicine (Baltimore).  2006 , 85, 147 -156. 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 72 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 Klein, R.S.; Morganroth, P.A.; Werth, V .P. Cutaneous Lupus and the CLASI instrument.  
Rheum. Dis. North Am.  2010 , 36, 33 -51. 
Mallinckrodt  Inc. Acthar Data Compendium . RD -010-00 internal data on file.  
Mallinckrodt Inc. H.P . Acthar® Gel ; Package Insert:  Hazelwood, MO,  2015 . 
Mallinckrodt Inc. H.P . Acthar® Gel ; Investigator ’s Brochure:  Hazelwood, MO,  2016. 
McElhone, K.; Abbott, J. Shelmerdine, J.; Bruce, J.; Ahmad, Y .; Gordon, C.; et al. 
Development  and Validation of Disease -specific Health -related Quality of Life M easure, the 
Lupus QOL, for A dults W ith Systemic Lupus Erythematosus. Arthritis Care Res.  2007 , 57, 
972-979. 
Mountjoy, K.G.; Robbins, L.S.;  Mortrud, M.T.; Cone, R.D. The C loning of a Family of G enes 
That E ncode th e Melanocortin R eceptors. Scienc e. 1992 , 257, 1248 -1251.  
Navarra, S.V .; Guzm án, R.M.; Gallacher, A.E .; Hall, S.; Levy, R.A.; Jimenez , R.E.; et al. 
Efficacy and Safety of Belimumab in Patients With Active Systemic Lupus Erythematosus: A 
Randomized, Placebo -controlled, Phase 3 Trial. Lancet . 2011 , 377, 721 -731. 
Olsen, N.J.; Decker, D.A.; Becker, P.A.; McAloose, C.A.; B enko, A.L.; Kovacs, W.J. Direct 
Effects of HP Acthar Gel on Human B Lymphocyte Activation In Vitro. Arthritis Res. Ther. 
2015 , 17, 300.  
Petri, M.; Buyon, J.; Kim, M.; Classification and Definition of Major Flares in Systemic 
Lupus Erythematosus  Clinical Tr ials. Lupus . 1999 , 8, 685 -691. 
Petri, M. Clinical Research in Systemic Lupus Erythematosus: Immediate Relevance to 
Clinical Practice. Int. J. Rheum. Dis.  2011 , 14, 1 -5. 
Schiöth, H.B.; Muceniece, R.; Wikberg, J.E.; Chhajlani, V . Characterization of melanoco rtin 
receptor subtypes by radioligand binding analysis. Eur. J. Pharmacol . 1995 , 15, 311 -317. 
Tan, E.M.; Cohen, A.S.; Fries, J.F., Masi, A.T.; McShane, D.J.; Rothfield, N.F.; at al. The 
1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis 
Rheum.  1982 , 25, 1271 -1277.  
Trager, J.; Ward, M.M. Mortality and Causes of Death in Systemic Lupus Erythematosus. 
Curr. Opin. Rheumatol.  2001 , 13, 345 -351. 

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 73 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 Urowitz, M.B.; Bookman, A.A.; Koehler, B.E.; Gordon, D.A.; Smythe, H.A.; Ogryzlo, M.A.; 
The Bimodal Mortality Pattern of Systemic Lupus Erythematosus. Am. J. Med.  1976 , 60, 221 -
225. 
V on Feldt, J.M. Systemic Lupus Erythematosus. Recognizing its Various Presentations. 
Postgrad. Med . 1995 , 97, 79 -86. 
Zhang, W.; Bansb ack, N.; Boonen, A.; Young, A.; Singh, A.; Anis, A.H. Validity of the Work 
Productivity and Activity Impairment Questionnaire – A General Health Version in Patients 
With Rheumatoid Arthritis. Arthritis Res . Ther.  2010,  12, R177.  
  

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 74 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 33 Attachments  
33.1 Attachment 1:  Clinical Laboratory Tests   
Serum Chemistry  
Alanine aminotransferase (ALT)  Creatine phosphokinase  
Albumin (total)  Creatinine  
Alkaline phosphatase  Glucose  
Aspartate aminotransferase  (AST)  Phosphorus  
Bilirubin (total)  Potassium  
Bicarbonate  Protein, total 
Blood urea nitrogen  Sodium  
Calcium  Uric acid  
Chloride   
Lipid Profile   
High density lipoprotein  Triglycerides  
Low density lipoprotein  Total cholesterol  
Hematology Assays  
Direct Coombs Test  (local laboratory)  Mean corpuscular volume  
Hematocrit  Platelet count  
Hemoglobin  Red blood cell count  
Haptoglobin  Reticulocyte count  
Mean corpuscular hemoglobin  White blood cell count, including differential   
Mean corpuscular hemoglobin concentration   
Urinalysis  
Color  Ketones  
Clarity  Protein  
Albumin  pH 
Bilirubin  Specific gravity  
Blood  Protein:creatinine ratio  
Creatinine  Microscopy (WBC/ high power field (HPF), RBC/HPF 
and urinary casts)  Glucose  
Diabetes Screen  
HbA1c  
Hormones  
Serum and urine beta -human chorionic gonadotropin (pregnancy test ; conducted on site )  
Other  
C3, C4, and ant -ds DNA antibodies   

Acthar® Gel (Repository Corticotropin Injection)   
Clinical Protocol MNK14 304067   
Revision Date:  01 June 2017  Page 75 of 75 
 
CONFIDENTIAL  
PROPRIETARY   Mallinckrodt  
 Hepatitis Serology  
Hepatitis B core antibody  Hepatitis C virus antibody  (HCV)  
Hepatitis B surface antigen  Hepatitis C virus PCR (only if HCV +)  
TB Assay  
Interferon gamma release assay (IGRA)  
 
